

ULUSOY UN SANAYİ VE TİCARET A.Ş.

CONVENIENCE TRANSLATION TO ENGLISH OF
AUDIT REPORT REGARDING FINANCIAL
STATEMENTS FOR THE PERIOD ENDED DECEMBER 31, 2014

Report Date: February 25, 2015
Report Number: AU/2015/003



DMR Bağımsız Denetim ve Danışmanlık A.Ş.

Cevizli Mah. Tugay Yolu Cad. Kurşunlu Sok. No:2
Teknik Yapı Deluxia Dragos K:21 D:421 34846
Maltepe - İstanbul

Web : www.dmr-tr.com
Tel : +90 216 338 00 72
Fax : +90 216 338 28 07
Tic.Sic.No. : 613023
Mersis No. : 0302051320300010

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

CONVENIENCE TRANSLATION TO ENGLISH OF AUDIT REPORT REGARDING FINANCIAL STATEMENTS FOR THE PERIOD ENDED DECEMBER 31, 2014

To the Board of Directors of Ulusoy Un Sanayi ve Ticaret A.Ş.

We have audited the accompanying financial statements of Ulusoy Un Sanayi ve Ticaret A.Ş. ("The Company") which comprise the statement of financial position as of December 31, 2014 and the profit or loss statement, the statement of other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes, a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's management is responsible for the preparation and fair presentation of these financial statements in accordance with the Turkish Accounting Standards ("TAS") published by the Public Oversight Accounting and Auditing Standards Authority of Turkey ("POA") and for such internal controls as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to error and/or fraud.

Auditors' Responsibility

Our responsibility is to express an opinion on the financial statements based on our audit. Our audit was conducted in accordance with the Independent Auditing Standards published by Capital Market Board ("CMB") and in accordance with Independent Audit Standards which are part of Turkish Auditing Standards issued by POA. These standards require that ethical requirements are complied with and that the audit is planned and performed to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence for the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments; The Company's internal control system is taken into consideration. Our purpose, however, is not to express an opinion on the effectiveness of internal control system, but to design procedures that are appropriate for the circumstances in order to identify the relation between the financial statements prepared by The Company and its internal control system. An audit includes also evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by The Company's management, as well as evaluating the overall presentation of the financial statements.



DMR
DMR Bağımsız Denetim ve Danışmanlık A.Ş.

DMR Bağımsız Denetim ve Danışmanlık A.Ş.
Cevizli Mah. Tugay Yolu Cad. Kurşunlu Sok. No:2
Teknik Yapı Deluxia Dragos K:21 D:421 34846
Maltepe - İstanbul

Web : www.dmr-tr.com
Tel : +90 216 338 00 72
Fax : +90 216 338 28 07
Tic.Sic.No. : 613023
Mersis No. : 0302051320300010

We believe that the audit evidence obtained is sufficient and adequate to provide a basis for our opinion.

Without qualifying our opinion, we would like to draw attention to note 42.

Opinion

In our opinion, accompanying financial statements present fairly, in all material respects, the financial position of The Company as of December 31, 2014 and their performance and cash flows for the year then ended in accordance with the Turkish Accounting Standards.

Reports Arising from Other Regulatory Requirements

- 1) Audit report on early risk identification system and committee, which has been prepared in accordance with 6102 numbered Turkish Commercial Code's ("TCC") 398th article in paragraph 4, has been submitted to The Company's Board of Directors on February 25, 2015.
- 2) In accordance with Article 402 of TTC, no significant matter has come to our attention that causes us to believe that The Company's bookkeeping activities for the period between January 1 and December 31, 2014, is not in compliance with the code and provisions of The Company's articles of association that are related with financial reporting. Also, The Board of Directors submitted to us the necessary explanations and provided required documents within the context of audit.

İstanbul, 25.02.2015

DMR BAĞIMSIZ DENETİM VE DANIŞMANLIK ANONİM ŞİRKETİ
A member firm of Kudos International Network



Ömer LALİK
Partner

INDEX	<u>Page</u>
STATEMENT OF FINANCIAL POSITION	1-2
PROFIT OR LOSS STATEMENT	3
STATEMENT OF OTHER COMPREHENSIVE INCOME	4
STATEMENT OF CHANGES IN EQUITY	5
STATEMENT OF CASH FLOWS	6
NOTES TO THE FINANCIAL STATEMENTS	7-55
1. ORGANIZATION AND OPERATIONS OF THE COMPANY	7
2. BASIS OF THE FINANCIAL STATEMENTS	8
3. BUSINESS COMBINATIONS	19
4. BUSINESS PARTNERSHIP	19
5. SEGMENTAL REPORTING	19
6. CASH AND CASH EQUIVALENTS	20
7. FINANCIAL INVESTMENTS	20
8. FINANCIAL BORROWINGS	20
9. OTHER FINANCIAL LIABILITIES	23
10. TRADE RECEIVABLES AND PAYABLES	23
11. OTHER RECEIVABLES AND PAYABLES	24
12. RECEIVABLES AND PAYABLES FROM FINANCE SECTOR OPERATIONS	24
13. DERIVATIVE INSTRUMENTS	24
14. INVENTORIES	24
15. BIOLOGICAL ASSETS	25
16. PREPAID EXPENSES AND DEFERRED INCOME	25
17. RECEIVABLES FROM ONGOING CONSTRUCTION CONTRACTS	25
18. INVESTMENTS VALUED BY EQUITY METHOD	25
19. INVESTMENT PROPERTIES	27
20. CORPORATE TAX ASSETS	27
21. TANGIBLE ASSETS	28
22. INTANGIBLE ASSETS	31
23. GOVERNMENT GRANTS AND INCENTIVES	32
24. PROVISIONS, CONTINGENT ASSETS AND LIABILITIES	32
25. COMMITMENTS	32
26. EMPLOYEE BENEFITS	33
27. RETIREMENT BENEFITS	34
28. OTHER ASSETS AND OTHER LIABILITIES	34
29. EQUITY	35
30. REVENUE AND COST OF SALES	40
31. GENERAL ADMINISTRATIVE EXPENSES, MARKETING EXPENSES, RESEARCH AND DEVELOPMENT EXPENSES	41
32. OTHER INCOME AND OTHER EXPENSES	43
33. SHARES OF INVESTMENTS EVALUATED BY EQUITY METHOD IN PROFIT/LOSS	43
34. FINANCIAL INCOME AND EXPENSES	44
35. FIXED ASSETS HELD FOR SALE AND CEASED OPERATIONS	44
36. TAX ASSETS AND TAX LIABILITIES	44
37. EARNINGS PER SHARE	47
38. RELATED PARTY DISCLOSURES	47
39. NATURE AND EXTENT OF RISK ARISING FROM FINANCIAL INSTRUMENTS	50
40. FINANCIAL INSTRUMENTS (FAIR VALUE EXPLANATIONS AND EXPLANATIONS OF HEDGE ACCOUNTING)	50
41. SUBSEQUENT EVENTS	55
42. OTHER MATTERS THAT MAY AFFECT THE FINANCIAL STATEMENTS TO A SIGNIFICANT EXTENT OR MATTERS WHICH ARE REQUIRED TO BE EXPLAINED IN ORDER FOR THE FINANCIAL STATEMENTS TO BE CLEAR, INTERPRETABLE AND UNDERSTANDABLE	55

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

AUDITED STATEMENT OF FINANCIAL POSITION AS OF DECEMBER 31,2014
(Amounts expressed in TL, unless otherwise is stated.)

ASSETS	Note	31.12.2014	(Restated*) 31.12.2013
Current Assets		440.546.330	288.866.127
Cash and Cash Equivalents	6	66.466.944	63.983.460
Financial Investments	7	256.679	10.557
Trade Receivables	10	177.055.422	103.894.335
Receivables from Finance Sector Operations	12	-	-
Other Receivables	11	878.777	3.429.237
Derivative Financial Instruments	13	3.770.212	3.314.950
Inventories	14	175.012.462	104.017.540
Biological Assets	15	-	-
Prepaid Expenses	16	14.140.472	8.651.196
Corporate Tax Assets	20	374.740	-
Other Current Assets	28	2.590.622	1.564.852
<i>(Sub Total)</i>		<i>440.546.330</i>	<i>288.866.127</i>
Fixed Assets Held for Sale	35	-	-
Non-Current Assets		53.336.233	51.116.025
Financial Investments	7	15.000	15.000
Trade Receivables	10	-	-
Receivables from Financial Sector Activities	12	-	-
Other Receivables	11	34.051	142.153
Derivative Financial Instruments	13	-	-
Investments Valued by Equity Method	18	4.256.112	4.250.000
Biological Assets	15	-	-
Investment Properties	19	-	-
Tangible Assets	21	47.524.698	46.236.180
Intangible Assets	22	50.134	49.488
-Goodwill	22	-	-
-Other Intangible Assets	22	50.134	49.488
Prepaid Expenses	16	1.502	-
Deferred Tax Assets	36	1.454.736	423.204
Other Non-Current Assets	28	-	-
TOTAL ASSETS		493.882.563	339.982.152

*(Vide Note 2)

Financial statements for the period ended December 31, 2014 were approved at the board meeting on February 25, 2014 and signed by Fahrettin ULUSOY, Nevin ULUSOY, Kamil ADEM, Mithat DENİZCİGİL and Kemal KİTAPLI on behalf of the Board of Directors.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

AUDITED STATEMENT OF FINANCIAL POSITION AS OF DECEMBER 31,2014
(Amounts expressed in TL, unless otherwise is stated.)

LIABILITIES	Note	31.12.2014	(Restated*) 31.12.2013
Short Term Liabilities		319.988.236	244.262.605
Short Term Financial Borrowings	8	36.457.969	17.050.569
Short Term Portions of Long Term Financial Borrowings	8	7.339.321	2.100.382
Other Financial Liabilities	9	-	-
Trade Payables	10	263.547.230	221.397.906
Payables from Finance Sector Operations	12	-	-
Payables Related with Employee Benefits	26	387.692	301.943
Other Payables	11	30.366	618
Derivative Financial Instruments	13	-	-
Government Grants	23	-	-
Deferred Incomes	16	-	-
Corporate Tax Liabilities	36	1.026.155	142.466
Short Term Provisions	24	-	-
-Short Term Provisions for Employee Benefits	26/24	-	-
-Other Short Term Provisions	24	-	-
Other Short Term Liabilities	28	11.199.503	3.268.721
(Sub Total)		319.988.236	244.262.605
Liabilities of Fixed Assets Held for Sales Purpose	35	-	-
Long Term Liabilities		11.005.694	8.327.037
Long Term Financial Borrowings	8	3.173.288	1.713.933
Other Financial Liabilities	9	-	-
Trade Payables	10	-	-
Payables from Finance Sector Operations	12	-	-
Other Payables	11	-	2.120
Derivative Financial Instruments	13	-	-
Government Grants	23	-	-
Deferred Incomes	16	-	-
Long Term Provisions	24	607.917	543.165
-Long Term Provisions for Employee Benefits	26/24	607.917	543.165
-Other Long Term Provisions	24	-	-
Corporate Tax Liabilities		-	-
Deferred Tax Liabilities	36	7.224.489	6.067.819
Other Long Term Liabilities	28	-	-
Shareholder's Equity	29	162.888.633	87.392.510
Paid in Capital		84.500.000	50.000.000
Share Premiums on Capital Stock		38.607.992	-
Accumulated Other Comprehensive (Income) Expenses not to be Reclassified in Profit and (Loss)		21.716.201	21.877.446
Accumulated Other Comprehensive (Income) Expenses not to be Reclassified in Profit and (Loss)		21.763.600	21.905.713
-Actuarial Gains/ (Losses) Related to Employee Benefit		(47.399)	(28.267)
Other Accumulated Comprehensive Income or Expenses to be Classified in Profit or (Loss)		-	-
- Hedging Gains/(Losses)		-	-
Other Reserves		-	4.999.928
Restricted Reserves		1.400.369	1.050.779
Retained Earnings		2.474.682	1.415.578
Net Profit/(Loss) for the Period		14.189.389	8.048.779
TOTAL LIABILITIES		493.882.563	339.982.152

*(Vide Note 2)

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

AUDITED PROFIT OR LOSS STATEMENT FOR THE PERIOD BETWEEN JANUARY 1 -
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

	Note	January 1- December 31, 2014	(Restated*) January 1 - December 31, 2013
OPERATING ACTIVITIES			
Revenue	30	921.577.365	682.163.343
Cost of Sales (-)	30	(862.192.903)	(633.783.566)
Gross Profit/Loss From Commercial Activity		59.384.462	48.379.777
Income from Financial Sector Activities		-	-
Cost of Financial Sector Activities (-)		-	-
Gross Profit/(Loss) From Financial Sector Activities		-	-
GROSS PROFIT/(LOSS)		59.384.462	48.379.777
General Administrative Expenses (-)	31	(5.234.767)	(4.253.659)
Marketing Expenses (-)	31	(20.335.403)	(17.759.151)
Research and Development Expenses (-)	31	-	-
Other Operating Income	32	4.809.953	5.374.244
Other Operating Expenses (-)	32	(3.773.614)	(2.916.287)
OPERATING PROFIT/(LOSS)		34.850.631	28.824.924
Income from Investing Activities		-	-
Expenses from Investing Activities		-	-
Shares of Investments Evaluated by Equity Method in Profit/(Loss)	33	323.509	-
OPERATING PROFIT/(LOSS) BEFORE FINANCIAL EXPENSE		35.174.140	28.824.924
Financial Income	34	86.195.073	49.744.700
Financial Expenses (-)	34	(103.822.184)	(67.937.188)
CONTINUING OPERATIONS PROFIT/(LOSS) BEFORE TAX		17.547.029	10.632.436
Continuing Operations Tax Income/(Expenses)	36	(3.357.640)	(2.583.657)
Current Period Tax Income/(Expenses)		(3.192.191)	(1.992.182)
Deferred Tax Income/(Expenses)		(165.449)	(591.475)
CONTINUING OPERATIONS PROFIT/(LOSS) FOR THE PERIOD		14.189.389	8.048.779
DISCONTINUED OPERATIONS PROFIT/(LOSS) FOR THE PERIOD		-	-
The Profit/(Loss) of Discontinued Operations After Tax		-	-
NET PROFIT/(LOSS) FOR THE PERIOD		14.189.389	8.048.779
Net Profit/(Loss) Attributable To:		14.189.389	8.048.779
Non-Controlling Interest		-	-
Equity Holders of The Parent Company		14.189.389	8.048.779
Earnings Per Share	37	0,1679	0,1609
Earnings Per Share from Continuing Operations		0,1679	0,1609
Earnings Per Share from Discontinued Operations		-	-
Diluted Earnings Per Share		-	-
Diluted Earnings Per Share From Continuing Operations		-	-
Diluted Earnings Per Share From Discontinued Operations		-	-

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

AUDITED STATEMENT OF OTHER COMPREHENSIVE INCOME FOR THE PERIOD BETWEEN
JANUARY 1 – DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

	Note	January 1- December 31, 2014	(Restated*) January 1 - December 31, 2013
OTHER COMPREHENSIVE INCOME			
Not to be Classified in Profit or (Loss)	29	(161.245)	21.237.514
Tangible Assets Revaluation Increases/(Decreases)		(177.641)	26.582.227
Intangible Assets Revaluation Increases/(Decreases)		-	-
Defined Benefit Plans Revaluation Gains/(Losses)		(23.915)	(35.334)
Shares Not to be Classified to Profit/(Loss) from Other Comprehensive Income of Investment Valued By Equity Method		-	-
Other Comprehensive Income Items Not to Classify to Other Profit/(Loss)		-	-
Taxes Related to Other Comprehensive Income Not to Reclassified to Profit/(Loss)		40.311	(5.309.379)
<i>Current Period Tax Income / (Expenses)</i>		-	-
<i>Deferred Tax Income / (Expenses)</i>		40.311	(5.309.379)
To be Classified in Profit or (Loss)		-	-
Foreign Currency Conversion Adjustments		-	-
Revaluation and/or Classification Gains/(Losses) of Available For Sale Financial Assets		-	-
Cash Flow Hedge Gains/(Losses)		-	-
Investment Hedge Gains/(Losses) Related to Foreign Business		-	-
Shares to be Classified in Profit/(Loss) from Other Comprehensive Income of Investment Valued By Equity Method		-	-
Other Comprehensive Income Items to Classify to Other Profit/(Loss)		-	-
Taxes Related to Other Comprehensive Income to Reclassify to Profit/(Loss)		-	-
<i>Current Period Tax Income / (Expenses)</i>		-	-
<i>Deferred Tax Income / (Expenses)</i>		-	-
OTHER COMPREHENSIVE INCOME		(161.245)	21.237.514
TOTAL COMPREHENSIVE INCOME		14.028.144	29.286.293
Total Comprehensive Income Attribute To:		14.028.144	29.286.293
Non-Controlling Interest		-	-
Equity Holders of The Parent Company		14.028.144	29.286.293

*(Vide Note 2)

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

AUDITED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD BETWEEN JANUARY 1 – DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

	Note	Accumulated Other Comprehensive Income or Expenses Not To Be Reclassified Under Profit Or Loss				Other Accumulated Comprehensive Income or Expenses to Be Classified in Profit or Loss				Accumulated Profit/(Loss)		Total
		Paid in Capital	Tangible Assets Revaluation Fund	Actuarial Gains/(Losses) Related to Employee Benefits	Share Premiums on Capital Stock	Restricted Reserves	Hedging Gains/(Losses)	Other Reserves	Special Funds**	Retained Earnings	The Profit/(Loss) of Period	
December 31, 2012 Balance		38.000.000	639.932	-	-	767.184	-	-	533.239	3.127.837	4.133.133	47.201.325
Transfer to Retained Earnings	29	-	-	-	-	283.595	-	-	-	3.849.538	(4.133.133)	-
Increase/Decrease Due to Other Changes		-	-	-	-	-	-	4.999.928	-	-	-	4.999.928
Capital Contribution	29	12.000.000	-	-	-	-	-	-	(533.239)	(5.561.797)	-	5.904.964
Total Comprehensive Income	26/29	-	21.265.781	(28.267)	-	-	774.309	-	-	-	7.274.470	29.286.293
December 31, 2013 Balance		50.000.000	21.905.713	(28.267)	-	1.050.779	774.309	4.999.928	-	1.415.578	7.274.470	87.392.510
Change in Accounting Policies*	-	-	-	-	-	-	(774.309)	-	-	-	774.309	-
Transfer to Retained Earnings	-	-	-	-	-	349.590	-	-	-	7.699.189	(8.048.779)	-
Capital Contribution**	-	15.000.000	-	-	-	-	-	(4.999.928)	-	(6.642.206)	-	3.357.866
Adjustments	-	-	-	-	-	-	-	-	-	2.121	-	2.121
Public Offer	-	19.500.000	-	-	38.607.992	-	-	-	-	-	-	58.107.992
Total Comprehensive Income	-	-	(142.113)	(19.132)	-	-	-	-	-	-	14.189.389	14.028.144
December 31, 2013 Balance		84.500.000	21.763.600	(47.399)	38.607.992	1.400.369	-	-	-	2.474.682	14.189.389	162.888.633

*(Vide Note 2)

** (Vide Note 29)

ULUSOY UN SANAYİ VE TİCERET ANONİM ŞİRKETİ

AUDITED STATEMENT OF CASH FLOWS FOR THE PERIOD BETWEEN JANUARY 1 – DECEMBER 31, 2014 (Amounts expressed in TL, unless otherwise is stated.)

		(Restated*)	
	Note	January 1- December 31, 2014	January 1- December 31, 2013
A. Cash Flow From Operating Activities		(75.614.442)	89.612.015
Net Profit/(Loss) For The Period	29	14.189.389	8.048.779
Adjustment Related to Period Profit/Loss Agreement		7.505.610	(1.374.521)
Adjustments Related to Depreciation and Amortisation Expense	31	1.420.797	1.257.156
Adjustments Related to Interest Income/Expense		5.878.528	(3.233.454)
Adjustments Related to Provisions		47.905	10.302
Adjustments Related to Tax Income/Expense		158.380	591.475
Changes in Working Capital		(97.309.441)	82.937.757
Adjustments Related to Increase/Decrease in Inventories	14	(70.994.922)	34.002.255
Adjustments Related to Increase/Decrease in Trade Receivables	10	(73.161.087)	(15.787.362)
Adjustments Related to Increase/Decrease in Other Receivables	11	2.658.562	(2.558.258)
Adjustments Related to Increase/Decrease in Trade Payables	10	42.149.324	73.153.852
Adjustments Related to Increase/Decrease in Other Payables	11	27.628	(450.949)
Adjustments Related to Other Increase/Decrease in Working Capital		2.011.054	(5.421.781)
B. Cash Flows From Investing Activities		12.355.809	6.006.404
Purchase /Disposal of Tangible and Intangible Asset	21/22	(2.887.602)	(889.890)
Cash Outflows for Debt Instruments or Shares of Other Companies or Funds		(252.234)	(4.265.557)
Cash Outflows Regarding Debt Payments	13	(455.262)	153.577
Received Interest	34	15.950.907	11.008.274
C. Cash Flows From Financing Activities		65.742.117	(38.257.040)
Capital Contribution	29	61.465.858	5.904.964
Cash Inflows from Financial Borrowings		732.271.269	106.940.133
Cash Outflows from Derivative Instruments		(703.057.526)	(141.031.275)
Interest Paid	34	(24.937.484)	(15.070.790)
Other Cash Inflows		-	4.999.928
Net Increase/(Decrease) in Cash and Cash Equivalents Before The Effect Of Foreign Currency Exchange Differences (A+B+C)		2.483.484	57.361.379
D. Effect of Foreign Currency Exchange Adjustments on Cash and Cash Equivalents		-	-
Net Increase/Decrease in Cash and Cash Equivalents (A+B+C+D)		2.483.484	57.361.379
E. Cash and Cash Equivalents at the Beginning of the Period	6	63.983.460	6.622.081
Cash and Cash Equivalents at the End of the Period (A+B+C+D+E)	6	66.466.944	63.983.460

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

1. ORGANIZATION AND OPERATIONS OF THE COMPANY

Ulusoy Un Sanayi ve Ticaret Anonim Şirketi ("The Company") was established in 1989 to produce, trade, export and import all kinds of food products from cereals and legumes.

The Company's registered head office address is Atatürk Bulvarı No: 272 Kutlukent / Samsun.

The Company's registered capital ceiling is 150.000.000-TL. The permission of registered capital ceiling given by Capital Market Board ("CMB") is valid between 2013 – 2017 (for 5 Years).

In the meeting dated November 7, 2014 and numbered 32/1095, CMB has allowed The Company to public offer on November 12-13-14, 2014 by book building (demand gathering) method. Total of 23.500.000 TL nominal value shares, which were offered to public by capital increase and sales of shareholders, were sold. 27,81% of The Company shares has been traded in Borsa İstanbul since November 20, 2014. The issued capital of The Company is 84.500.000 TL (Eightyfourmillion and fivehundredthousand Turkish Lira). This capital consists of 9.750.000 Group A shares, 6.500.000 Group B shares and 68.250.000 Group C shares and each worths 1,00TL that makes a total of 84.500.000 TL. Group A and B shares are registered to the name and Group C shares which are traded in Borsa İstanbul are registered to the bearer, other Group C shares are registered to the name. Group A shares have privilege to vote in the election of Board of Directors, Group A and B shares have privilege to vote in General Assembly and not considering independent members, in case the Board of Directors consist of five members, at least two members, in case it consists of six or seven members, at least three members, in case it consists of eight or nine members, at least four members, in case it consists of ten or eleven members, at least five members must be chosen among the candidates who are nominated by the majority of Group A shareholders. Group A shareholders or representatives have 15 votes, Group B shareholders or representatives have 10 votes, Group C shareholders or representatives have 1 vote for each share in the ordinary or extraordinary General Assembly.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Partnership structure of The Company is as follows:

Shareholder	Number of Shares	Group	Rate (%)	Amount
Fahrettin Ulusoy	4.550.000	A	5,38	4.550.000
	1.950.000	B	2,31	1.950.000
	23.873.882	C	28,25	23.873.882
	30.373.882		35,94	30.373.882
Nevin Ulusoy	650.000	A	0,77	650.000
	1.300.000	B	1,54	1.300.000
	5.830.756	C	6,90	5.830.756
	7.780.756		9,21	7.780.756
Onur Erhan Ulusoy	650.000	A	0,77	650.000
	1.950.000	B	2,31	1.950.000
	7.423.684	C	8,78	7.423.684
	10.023.684		11,86	10.023.684
Eren Günhan Ulusoy	3.900.000	A	4,62	3.900.000
	1.300.000	B	1,54	1.300.000
	7.499.375	C	8,88	7.499.375
	12.699.375		15,04	12.699.375
Kamil Adem	26.941	C	0,03	26.941
	26.941		0,03	26.941
Mithat Denizcigil	95.362	C	0,11	95.362
	95.362		0,11	95.362
Public Shares	23.500.000	C	27,81	23.500.000
	84.500.000		100,00	84.500.000

The Company has 193 employees as of December 31, 2014 (December 31, 2013:166 employees).

2. BASIS OF THE FINANCIAL STATEMENTS

2.1. Basis of Presentation

2.1.1. Statement of Compliance

The Company prepares its accounting records in accordance with the accounting principles of Turkish Commercial Code and Turkish Tax Law and prepares legal financial statements in Turkish Lira (TL).

The accompanying financial statements are prepared in accordance with the Turkish Accounting Standards ("TAS") / Turkish Financial Reporting Standards ("TFRS"), which are endorsed by the Public Oversight Accounting and Auditing Standard Authority according to Communique No:II, 14.1 "Communique on Financial Reporting Standards in Capital Markets" ("the Communique")

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

promulgated by CMB, which is published in the Official Gazette dated June 13, 2013 and numbered 28676.

Financial statements for the period ended December 31, 2014 were approved at the board meeting on February 25, 2015 and signed by Fahrettin ULUSOY, Nevin ULUSOY, Kamil ADEM, Mithat DENİZCİGİL and Kemal KİTAPLI on behalf of the Board of Directors.

The Company's General Assembly and/or legal authorities have the authority to change the accompanying financial statements.

2.1.2. Basis of Financial Statements Preparation

The financial statements as of December 31, 2014 are prepared in accordance with the Communiqué.

Paid in capital and restricted reserves are expressed by the amounts in legal records.

The accompanying financial statements contain adjustments and classifications of The Company's legal records according to the Communiqué.

The financial statements and notes were prepared in accordance with the formats required by CMB's communiqués and decrees.

The Company's financial statements are prepared in accordance with The Company's sustainability.

2.1.3. Reporting Currency

The accompanying financial statements are presented in TL and all financial information is rounded to the nearest digit.

2.1.4. Adjustment of Financial Statements in Hyperinflation Period

TAS 29 requires that financial statements prepared in the currency of a hyperinflationary economy should be stated in terms of the measuring unit current at the balance sheet date. Hyperinflation period ceased and also the criteria related to hyperinflation are not valid anymore according to CMB's March 17, 2005 dated and 11/367 numbered decree. Moreover, preparation of financial statements according to inflation accounting has been ceased on January 1, 2005.

2.1.5. Basis of Consolidation

The Company does not have any consolidated subsidiary within the scope of TAS 27 and TFRS 10. The financial statements as of December 31, 2014 and December 31, 2013 are presented as non-consolidated financial statements.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

2.1.6. Comparative Information and Prior Period Financial Statement Correction

Financial statements are presented comparatively. Comparative information is reclassified in order to be in conformity with the presentation of the current financial statements if necessary.

Wheat sales commission of trust income consists of the commission income that are charged by The Company for importing on behalf of the firms that own Inward Processing Authorisation Certificate. The cost regarding the purchase of trust wheat is being reported as cost of trade goods and sales amount is reported as revenue. While commission income of trust wheat sales were classified in other income in the financial statements as of December 31, 2013, they have been reported in revenues as of December 31, 2014 for more sufficient and trustful presentation and considering the risk and income of this operation belongs to The Company. The trust expenses and revenues occur from the reflection of trust expenses are recognised as other operating income and expenses.

The effect of reclassification on financial statements as of December 31, 2013 is as follows:

	January 1- December 31, 2013	Reclassified January 1- December 31, 2013
OPERATING ACTIVITIES		
Revenue	681.123.194	682.163.343
Cost of Sales (-)	(633.783.566)	(633.783.566)
Gross Profit/(Loss) From Commercial Activity	47.339.628	48.379.777
Income from Financial Sector Activities	-	-
Cost of Financial Sector Activities (-)	-	-
Gross Profit/(Loss) From Financial Sector Activities	-	-
GROSS PROFIT/(LOSS)	47.339.628	48.379.777
General Administrative Expenses (-)	(4.253.659)	(4.253.659)
Marketing Expenses (-)	(17.759.151)	(17.759.151)
Research and Development Expenses (-)	-	-
Other Operating Income	6.414.393	5.374.244
Other Operating Expenses (-)	(2.916.287)	(2.916.287)
OPERATING PROFIT/(LOSS)	28.824.924	28.824.924

2.1.7. Offsetting

Financial assets and liabilities are reported on net basis in the statement of financial position; if there is legal offsetting right, they are paid on net basis or collection is possible or acquisition and payment are realised simultaneously.

2.1.8. Changes in Accounting Policies

Changes in accounting policies are applied retroactively and the financial statements of the prior period are prepared accordingly.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Changes in accounting policies applied for derivative instruments

While derivative instruments were recognised as derivative instruments for hedging as of December 31, 2013, they have been recognised as derivative instruments held for trading since December 31, 2014 for not fulfilling the conditions due to 88th article of TAS 39 "Financial Instruments: Recognition and Measurement". This change in accounting policies are realised by considering more sufficient and trustful presentation of derivative instruments in the financial statements within the scope of TAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors". The Company applies this change retrospectively and recognises derivative instruments as derivative instruments held for trading in financial statements as of December 31, 2013. As of December 31, 2013, the net hedging gain amount of 774.309-TL used to be recognised in other comprehensive income; but as a result of "the effect of change in accounting policies", it is recognised in profit or loss statement. This difference is presented as "change in accounting policies" in statement of shareholders' equity.

While The Company continues to classify derivative financial instruments as hedging financial assets, protection is not effective, therefore they do not have any effect on equity.

The effect of accounting policy change on derivative instruments for the prior period is as follows:

	31.12.2013 Before the Accounting (Reclassified) Policy Change	31.12.2013	Adjustment
Paid in Capital	50.000.000	50.000.000	-
Accumulated Other Comprehensive (Income) Expenses not to be Reclassified under Profit and (Loss)	21.877.446	21.877.446	-
-Revaluation and Measurement Gains/(Losses)	21.905.713	21.905.713	-
-Actuarial Gains/ (Losses) Related to Employee Benefit	(28.267)	(28.267)	-
Other Accumulated Comprehensive Income or Expenses to be Classified in Profit or (Loss)	774.309	-	(774.309)
- Hedging Gains/(Losses)	774.309	-	(774.309)
Other Reserves	4.999.928	4.999.928	-
Restricted Reserves	1.050.779	1.050.779	-
Retained Earnings	1.415.578	1.415.578	-
Net Profit/(Loss) for The Period	7.274.470	8.048.779	774.309
Shareholders' Equity	87.392.510	87.392.510	-

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

The effect of accounting policy change on derivative instruments in the profit or loss statement is as follows:

	January 1- December 31, 2013	(Reclassified) January 1- December 31, 2013	Adjustment
OPERATING ACTIVITIES			
Revenue	682.163.343	682.163.343	-
Cost of Sales (-)	(633.783.566)	(633.783.566)	-
Gross Profit/Loss From Commercial Activity	48.379.777	48.379.777	-
Income from Financial Sector Activities	-	-	-
Cost of Financial Sector Activities (-)	-	-	-
Gross Profit/Loss From Financial Sector Activities	-	-	-
GROSS PROFIT/(LOSS)	48.379.777	48.379.777	-
General Administrative Expenses (-)	(4.253.659)	(4.253.659)	-
Marketing Expenses (-)	(17.759.151)	(17.759.151)	-
Research and Development Expenses (-)	-	-	-
Other Operating Income	5.374.244	5.374.244	-
Other Operating Expenses (-)	(2.916.287)	(2.916.287)	-
OPERATING PROFIT/(LOSS)	28.824.924	28.824.924	-
Income from Investing Activities	-	-	-
Expenses from Investing Activities	-	-	-
Shares of Investments Evaluated by Equity Method in Profit/Loss	-	-	-
OPERATING PROFIT/(LOSS) BEFORE FINANCE EXPENSE	28.824.924	28.824.924	-
Financial Income	42.392.710	49.744.700	7.351.990*
Financial Expenses (-)	(61.359.507)	(67.937.188)	(6.577.681)*
CONTINUING OPERATIONS PROFIT/(LOSS) BEFORE TAX	9.858.127	10.632.436	774.309
Continuing Operations Tax Income/(Expenses)	(2.583.657)	(2.583.657)	-
Current Period Tax Income/(Expenses)	(1.992.182)	(1.992.182)	-
Deferred Tax Income/(Expenses)	(591.475)	(591.475)	-
CONTINUING OPERATIONS PROFIT/(LOSS) FOR THE PERIOD	7.274.470	8.048.779	774.309
DISCONTINUED OPERATIONS PROFIT/(LOSS) FOR THE PERIOD	-	-	-
The Profit/(Loss) of Discontinued Operations After Tax	-	-	-
NET PROFIT/(LOSS) FOR THE PERIOD	7.274.470	8.048.779	774.309
Net Profit/(Loss) Attributable To:	7.274.470	8.048.779	774.309
Non-Controlling Interest	-	-	-
Equity Holders of The Parent Company	7.274.470	8.048.779	774.309
Earnings Per Share	0,1454	0,1609	-
Earnings Per Share from Continuing Operations	0,1454	0,1609	-
Earnings Per Share from Discontinued Operations	-	-	-
Diluted Earnings Per Share	-	-	-
Diluted Earnings Per Share From Continuing Operations	-	-	-
Diluted Earnings Per Share From Discontinued Operations	-	-	-

* Consists of the financial gains and losses from derivative instruments such as forward, option and derivatives exchange collateral.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

The effect of accounting policy change on derivative instruments in the statement of other comprehensive income is as follows:

	January 1- December 31, 2013	(Reclassified) January 1- December 31, 2013	Adjustment
OTHER COMPREHENSIVE INCOME			
Not to be Classified in Profit or (Loss)	21.237.514	21.237.514	-
Tangible Assets Revaluation Increases/(Decreases)	26.582.227	26.582.227	-
Intangible Assets Revaluation Increases/(Decreases)	-	-	-
Defined Benefit Plans Revaluation Gains/(Losses)	(35.334)	(35.334)	-
Shares Not to be Classified to Profit/(Loss) from Other Comprehensive Income of Investment Valued By Equity Method	-	-	-
Other Comprehensive Income Items Not to Classify to Other Profit/(Loss)	-	-	-
Taxes Related to Other Comprehensive Income Not to Reclassified to Profit/(Loss)	(5.309.379)	(5.309.379)	-
<i>Current Period Tax Income / Expenses</i>	-	-	-
<i>Deferred Tax Income / Expenses</i>	(5.309.379)	(5.309.379)	-
To be Classified in Profit or Loss	774.309	-	774.309
Foreign Currency Conversion Adjustments	-	-	-
Revaluation and/or Classification Profit/(Loss) of Available For Sale Financial Assets	-	-	-
Cash Flow Hedge Gains/(Losses)	774.309	-	774.309
Investment Hedge Gains/(Losses) Related to Foreign Business	-	-	-
Shares to be Classified in Profit/(Loss) from Other Comprehensive Income of Investment Valued By Equity Method	-	-	-
Other Comprehensive Income Items to Classify to Other Profit/(Loss)	-	-	-
Taxes Related to Other Comprehensive Income to Reclassify to Profit/(Loss)	-	-	-
<i>Current Period Tax Income / Expenses</i>	-	-	-
<i>Deferred Tax Income / Expenses</i>	-	-	-
OTHER COMPREHENSIVE INCOME	22.011.823	21.237.514	774.309
TOTAL COMPREHENSIVE INCOME	29.286.293	29.286.293	-
Total Comprehensive Income Attribute To:	29.286.293	29.286.293	-
Non-Controlling Interest	-	-	-
Equity Holders Of The Parent Company	29.286.293	29.286.293	-

2.1.9. Changes in Accounting Estimates and Errors

If estimated changes in accounting policies are for only one period, changes are applied in the current period but if the estimated changes continue for the following periods, changes are applied both in the current and following periods prospectively. Determined accounting errors are applied retroactively and the financial statements of the prior periods are reprepared accordingly.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

2.1.10. Summary of Significant Accounting Policies

2.1.10.1. Revenue

Revenue is the gross inflow of economic benefits during the period arising in the course of the ordinary activities of The Company when those inflows result in increases in equity, other than increases relating to contributions from equity participants. Revenue includes only the gross inflows of economic benefits received and receivable by The Company on its own account. Revenue is recognised when it is probable that future economic benefits will flow to The Company and these benefits can be measured reliably and revenue shall be measured at the fair value of the consideration received or receivable. Net sales are calculated by deducting sales returns and sales discounts from gross sales.

Revenue from the sale of goods shall be recognised when all the following conditions have been satisfied:

- (a) The Company has transferred to the buyer the significant risks and rewards of ownership of the goods;
- (b) The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- (c) The amount of revenue can be measured reliably;
- (d) It is probable that the economic benefits associated with the transaction will flow to The Company;
- (e) The costs incurred or to be incurred in respect of the transaction can be measured reliably.

The Company's revenue is composed of wheat, corn, flour, bran, razmol and ear of wheat sales.

2.1.10.2. Tangible Assets

Tangible assets such as underground and overland plants, furniture and fixture, plants machinery and equipment of The Company are presented by their cost, including expenses incurred to make it ready for use, after deducting accumulated depreciation and accumulated impairment loss. As of December 31, 2014 and December 31, 2013; lands, buildings and vehicles are reported due to revaluation model in the financial statements and the realised difference is reported in equity in tangible assets revaluation fund and in the statement of other comprehensive income in the related period. When tangible assets are sold, realised profit or loss is presented in profit or loss statement after their cost and accumulated depreciation are deducted from the related accounts. Assets except lands are depreciated by considering the rates which are determined according to their useful lives.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

	<u>Useful Life</u>
Underground and Overland Plants	25-40-50 years
Buildings	25-50 years
Furniture and Fixture	3-4-5-6-9-10-15-16-50 years
Vehicles	2-4-5-10 years
Plants Machinery and Equipment	4-5-6-8-10-13-15-16 17-20-25-40-50 years

2.1.10.3. Intangible Assets

Intangible assets are recognised by acquisition cost and are amortized by the rates that are determined due to their useful lives.

	<u>Useful Life</u>
Rights	3-4-5-10-15 years

2.1.10.4. Impairment of Assets

All assets other than financial assets are tested for whether there is an indicator of impairment or not all balance sheet dates. If such an indicator exists, recoverable amount of that asset is estimated. Recoverable amount of an asset is the higher one of net selling price and value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its life.

2.1.10.5. Borrowing Costs:

All borrowing costs are recognised in income statement in the period in which they are incurred because The Company has no qualifying assets.

2.1.10.6. Inventories

Inventories shall be measured at the lower of cost and net realisable value. The cost of inventories shall comprise all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

2.1.10.7. Financial Assets

2.1.10.7.1. Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand and demand deposits and other short-term highly liquid investments of which maturities are three months or less from the date of acquisition and that are easily convertible to a known amount of cash and are subject to an insignificant risk of change in value. There are not significant differences between their book values and fair values.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

2.1.10.7.2. Trade and Other Receivables

Trade and other receivables are recorded by their fair values at the initial recognition, and are subsequently presented by amortized cost by using the effective interest rate method. Appropriate allowances for estimated irrecoverable amounts are recognised in profit or loss when there is objective evidence that the asset is impaired. Trade receivables and other receivables balances in the balance sheet are assumed to be their fair values.

2.1.10.7.3. Derivative Financial Instruments

Derivative financial instruments are held for trading or hedging. The Company holds all derivative financial instruments for trading. The difference between the cost value and the fair value of the financial derivative is recognised in profit/(loss).

2.1.10.7.4. Available-for-Sale Financial Assets

“Available-for-sale financial assets” are non-derivatives that are not designated in financial assets at fair value through profit or loss, held-to-maturity financial assets or loans and receivables. Available-for-sale equity securities that do not have quoted fair values or for which fair values cannot be reliably measured through alternative methods, are measured by deducting impairment provisions from its cost.

2.1.10.8. Financial Liabilities

2.1.10.8.1. Financial Borrowings

Interest-bearing financial borrowings are initially recognised by fair value, and are subsequently revaluated by using effective interest rate method.

2.1.10.8.2. Trade and Other Payables

Trade and other payables are initially recognised by fair value, and are subsequently evaluated by amortized cost by using effective interest rate method. It is assumed that there are not significant differences between book values and fair values of trade and other payables.

Credit Risk:

The Company’s credit risk primarily arises from its trade receivables. Trade receivables are evaluated by The Company’s management based on prior experiences and the current economic environment, and are presented in the balance sheet on net basis after deducting allowances for doubtful receivables.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Market Risk:

Market risk arises from the probable changes in the level of interest rates, currency exchange rates or the price of securities and other financial contracts that might have an adverse financial impact.

Liquidity Risk:

The Company is generally raising funds by liquidating its short-term financial instruments such as collecting its receivables and disposing of bank deposits. The proceedings from these instruments are presented by their fair values.

2.1.10.9. Foreign Currency Transactions

Transactions in foreign currencies are exchanged to TL by the rates on the date of transactions. Assets and liabilities denominated in foreign currencies are translated by the exchange rates on the balance sheet date. Gains and losses arising from settlement and translation of foreign currency items are presented in profit or loss statement.

2.1.10.10. Earnings Per Share

According to TAS 33; earnings per share presented in the accompanying profit or loss statement are calculated by dividing net income by the weighted average ordinary number of shares.

2.1.10.11. Subsequent Events

Describe the events that occurred between the reporting date and the authorization date for publishing the statement of financial position in favour of or against The Company. If there are new proofs showing that such events really exist as of balance sheet date or the related events reveal following balance sheet date, The Company states such issues in the related notes.

If some events that require adjustments revealed after balance sheet date, The Company should adjust the amounts in the financial statements according to the new situation.

2.1.10.12. Related Parties

For the purpose of accompanying financial statements, shareholders of The Company and other companies owned by the shareholders, their directors and key management personnel and any other related person or company are considered and referred as related parties. Related parties expression refers to the control of The Company directly or indirectly, to have right to provide significant impact on The Company or The Company's subsidiaries, members of the board, directors like chief executive officer.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

2.1.10.13. Taxes Calculated on The Basis Of The Company's Earnings

In Turkey, corporation tax rate is 20% for 2014. This rate is implemented to the tax base which is calculated by adding non-deductible expenses according to the tax laws and deducting tax exemptions and discounts. Unless the profit is distributed, there is not further tax to be paid.

Companies are required to pay temporary corporate tax based on their quarterly profits at the rate of 20%. Temporary Corporate tax must be submitted by the 14th of the second month following the quarterly period and the tax should be paid until the 17th of the same month. Temporary corporate tax payments are going to be offset against the final corporate tax liability of The Company, which is determined in the annual return. According to the Turkish Tax Laws, stated financial loss can be deducted from profit for five years.

2.1.10.14. Employee Termination Benefits

According to the laws in force, The Company is responsible for making a specific amount of payment to personnel due to rescind reasons except the ones stated in the Labour Law and retirement. Due to TAS 19 'Employee Benefits', employee termination benefits are presented in financial statements by estimating present value, of the total liability that should be paid to all employees who have right to get severance pay on balance sheet date.

2.1.10.15. Government Grants and Incentives

Government grants, including non-monetary grants at fair value, shall not be recognised until there is reasonable assurance that:

- (a) The Company will comply with the conditions attaching to them; and
- (b) the grants will be received.

The manner in which a grant is received does not affect the accounting method to be adopted in regard to the grant. Thus a grant is accounted for in the same manner whether it is received in cash or as a reduction of a liability to the government.

The benefit of a government loan at a below-market rate of interest is treated as a government grant. The loan shall be recognised and measured in accordance with TAS 39 Financial Instruments: Recognition and Measurement. The benefit of the below-market rate of interest shall be measured as the difference between the initial carrying value of the loan determined in accordance with TAS 39 and the proceeds received. The benefit is accounted for in accordance with this Standard. The Company shall consider the conditions and obligations that have been, or must be, met when identifying the costs for which the benefit of the loan is intended to compensate.

There are two broad approaches to the accounting for government grants: the capital approach, under which a grant is recognised outside profit or loss, and the income approach, under which a grant is recognised in profit or loss over one or more periods.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Considering income tax and other taxes are kinds of expense, as a part of financial policies the government grants, are recognised in profit or loss.

2.2. Significant Accounting Evaluation, Estimates and Judgments

The preparation of financial statements in accordance with TFRS, requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. If adjustment is necessary, it is reported in profit or loss statement of the period that adjustment is revealed.

2.3. New and Revised International Financial Reporting Standards

The Company applied all of the relevant and required standards promulgated by Public Oversight Accounting and Auditing Standard Authority as of December 31, 2014.

A number of new standards, amendments to standards and interpretations are not yet effective as of December 31, 2014 and have not been applied during the preparation of the accompanying financial statements. These standards are as follows;

TFRS 9 states two new measurement classification categories for financial assets: financial assets measured by amortized cost and financial assets measured by fair value. Companies' business model and the contractual cash flow characteristic of the financial assets are the basis of this classification. TFRS 9 is effective for the periods beginning on and after January 1, 2015, and an earlier application is permitted. It is not necessary to restate prior financial statements for the companies which adopt this standard before January 1, 2012.

In November 2013, the mandatory application date of IFRS 9 has been delayed to January 1, 2018 by International Accounting Standards Committee. However, this change has not been announced by Public Oversight Accounting and Auditing Standard Authority yet.

There are some new standards and some amendments related with some standards and comments which have not become valid as of December 31, 2014 and have not been considered while preparing the accompanying financial statements. These amendments are not expected to have an important effect over the accompanying financial statements.

3. BUSINESS COMBINATIONS

None.

4. BUSINESS PARTNERSHIP

None.

5. SEGMENTAL REPORTING

None.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

6. CASH AND CASH EQUIVALENTS

	Rate (%)	December 31, 2014	December 31, 2013
Cash		99.022	88.794
Demand Deposits		8.758.023	18.791.234
Deposit Accounts	Foreign Exchange:%2-%2,50-%2,70-%2,90 TL:%10-%10,50	54.230.901	43.967.126
POS Accounts		188.818	50.078
Investment and Fund Accounts		3.190.180	1.086.228
		66.466.944	63.983.460

7. FINANCIAL INVESTMENTS

Short Term Financial Investments

	December 31, 2014	December 31, 2013
Bonds	256.679	10.557

Long Term Financial Investments

Available for Sale Financial Assets	%	December 31, 2014	%	December 31, 2013
Samsun Teknolojik Geliştirme Bölgesi Yönetici A.Ş.	0,5	15.000	0,5	15.000
		15.000		15.000
Unpaid Capital Commitments (-)				
Samsun Teknolojik Geliştirme Bölgesi Yönetici A.Ş.				-
				-
Impairment Provisions (-)				
Samsun Teknolojik Geliştirme Bölgesi Yönetici A.Ş.				-
				-
		15.000		15.000

8. FINANCIAL BORROWINGS

Short Term Financial Borrowings

	December 31, 2014	December 31, 2013
Short Term Borrowings	36.457.969	17.050.569
Short Term Portions of Long Term Borrowings (net)	7.339.321	2.100.382
	43.797.290	19.150.951

Short Term Borrowings

	December 31, 2014	December 31, 2013
Short Term Loans	36.457.969	17.050.569

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Detail of the short term loans (net) as of December 31, 2014 is as follows:

Currency	Interest Rate	Currency Amount	TL Amount
USA Dollar	%2,10	3.000.000 USD	6.956.700
TL	%6-%6,09-%6,34-%7-%7,04-%7,29-%8,66	-	29.501.269
			36.457.969

Detail of the short term loans (net) as of December 31, 2013 is as follows:

Currency	Interest Rate	Currency Amount	TL Amount
Euro	Euribor+%4	750.000 Euro	2.202.375
TL	%4,25-%5-%6	-	14.848.194
			17.050.569

Short Term Portions of Long Term Borrowings

	December 31, 2014	December 31, 2013
Short Term Portions of Long Term Loans (net)	7.072.389	1.537.135
Short Term Portions of Long Term Leasing Payables (net)	266.932	563.247
	7.339.321	2.100.382

Short Term Portions Of Long Term Loans

	December 31, 2014	December 31, 2013
Short Term Portions of Long Term Loans	7.285.555	1.607.829
Deferred Interest Expenses (-)	(213.166)	(70.694)
Short Term Portions of Long Term Borrowings (net)	7.072.389	1.537.135

Detail of the short term portions of long term loans as of December 31, 2014 is as follows:

Currency	Interest Rate	Currency Amount	TL Amount
USA Dollar	-	-	-
Euro	Euribor+%3,5-Euribor+%2,5-Euribor+%3	2.507.317 Euro	7.072.389
TL	-	-	-
			7.072.389

Detail of the short term portions of long term loans as of December 31, 2013 is as follows:

Currency	Interest Rate	Currency Amount	TL Amount
ABD Doları	-	-	-
Euro	Euribor+%4	503.451 Euro	1.478.385
TL	%10,44	-	58.750
			1.537.135

Short Term Portions of Long Term Leasing Payables

	December 31, 2014	December 31, 2013
Short Term Portions of Long Term Leasing Payables	278.578	596.565
Deferred Interest Expenses (-)	(11.646)	(33.318)
Short Term Portions of Long Term Leasing Payables (net)	266.932	563.247

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Detail of the short term portions of long term leasing payables (net) as of December 31, 2014 is as follows:

Currency	Currency Amount	TL Amount
USA Dollar	115.111 USD	266.932
Euro	-	-
TL	-	-
		266.932

Detail of the short term portions of long term leasing payables (net) as of December 31, 2013 is as follows:

Currency	Currency Amount	TL Amount
USA Dollar	239.425 USD	511.005
Euro	17.791 Euro	52.242
TL	-	-
		563.247

Long Term Financial Borrowings

	December 31, 2014	December 31, 2013
Long Term Loans (net)	3.173.288	1.468.250
Long Term Leasing Payables (net)	-	245.683
Long Term Leasing Payables (net)	3.173.288	1.713.933

Long Term Loans

	December 31, 2014	December 31, 2013
Long Term Loans	3.213.863	1.497.662
Deferred Interest Expenses (-)	(40.575)	(29.412)
Long Term Loans (net)	3.173.288	1.468.250

Detail of the long term loans (net) as of December 31, 2014 is as follows:

Currency	Interest Rate	Currency Amount	TL Amount
USA Dollar	-	-	-
Euro	Euribor+%2,5 - Euribor+%3	1.125.000 Euro	3.173.288
TL	-	-	-
			3.173.288

Detail of the long term loans (net) as of December 31, 2013 is as follows:

Currency	Interest Rate	Currency Amount	TL Amount
USA Dollar	-	-	-
Euro	Euribor+%4	500.000 Euro	1.468.250
TL	-	-	-
			1.468.250

Long Term Leasing Payables

	December 31, 2014	December 31, 2013
Long Term Leasing Payables	-	256.402
Deferred Interest Expenses (-)	-	(10.719)
Long Term Leasing Payables (net)	-	245.683

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Detail of the long term leasing payables (net) as of December 31, 2013 is as follows:

Currency	Currency Amount	TL Amount
USA Dollar	115.111 USD	245.683
Euro	-	-
TL	-	-
		245.683

Redemption dates of long term loans as of December 31, 2014 and December 31, 2013 is as follows:

	December 31, 2014	December 31, 2013
To be paid in 2015	-	1.468.250
To be paid in 2016	3.173.288	-

9. OTHER FINANCIAL LIABILITIES

None.

10. TRADE RECEIVABLES AND PAYABLES

Trade Receivables

	December 31, 2014	December 31, 2013
Trade Receivables from Related Parties	-	-
Trade Receivables from Other Parties	152.160.986	78.014.436
Notes Receivable from Related Parties	1.831.879	379.459
Notes Receivable from Other Parties	24.337.775	26.726.768
Deferred Maturity Difference Income (-)	(1.275.218)	(1.226.328)
Doubtful Trade Receivables	4.317.305	3.263.026
Provision for Doubtful Trade Receivables (-)	(4.317.305)	(3.263.026)
Trade Receivables (net)	177.055.422	103.894.335

Changes in doubtful trade receivables as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Opening Balance	3.263.026	3.176.854
Provisions for the Period	1.211.143	480.134
Provisions Cancelled* (-)	(156.864)	(393.962)
Closing Balance	4.317.305	3.263.026

* Consists of collected doubtful trade receivables.

Trade Payables

	December 31, 2014	December 31, 2013
Trade Payables to Related Parties	315.135	360.172
Trade Payables to Other Parties*	262.653.097	221.993.512
Notes Payable to Related Parties	2.027.734	1.104.795
Notes Payable to Other Parties	1.868.862	282.810
Deferred Maturity Difference Expense (-)	(3.317.598)	(2.343.383)
Trade Payables (net)	263.547.230	221.397.906

*Trade payables to other parties include 255.986.073-TL letters of credit as of December 31, 2014.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

11. OTHER RECEIVABLES AND PAYABLES

Other Short Term Receivables

	December 31, 2014	December 31, 2013
Other Receivables from Related Parties	-	512.044
Other Receivables from Other Parties	-	1.829.181
Deposits and Guarantees Given	209.206	136.439
Receivables From Tax Department	669.571	951.573
	878.777	3.429.237

Other Long Term Receivables

	December 31, 2014	December 31, 2013
Deposits and Guarantees Given	34.051	142.153

Other Short Term Payables

	December 31, 2014	December 31, 2013
Other Payables to Other Parties	30.366	618

Other Long Term Payables

	December 31, 2014	December 31, 2013
Other Payables to Other Parties	-	2.120

12. RECEIVABLES AND PAYABLES FROM FINANCE SECTOR OPERATIONS

None.

13. DERIVATIVE INSTRUMENTS

	December 31, 2014	December 31, 2013
Futures Market Collaterals	1.485.123	3.314.950
Derivative Financial Instruments	2.285.089	-
	3.770.212	3.314.950

Collaterals that are given to make transactions in futures market are classified as futures market collaterals where as fair values of forward agreements and options are classified as derivative financial instruments. Profit or losses resulted from the transactions within the period are reported in profit/loss statement as derivative financial instruments gain/loss in financial income/expenses. Also, fair value differences of open positions as of reporting date are reported in financial income.

14. INVENTORIES

	December 31, 2014	December 31, 2013
Raw Material and Supplies	58.200.171	32.839.090
Goods	2.184.175	7.412.098
Trade Goods	111.634.890	61.340.352
Goods in transit*	2.943.252	-
Other Inventories	167.623	2.426.000
Provision for Impairment of Inventories (-)	(117.649)	-
	175.012.462	104.017.540

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

There are not any pledge, assurance and pawn upon inventories, and they are all insured.

* Goods in transit consist of products which are waiting in customs and of which sales agreement has been done and shipped but discharge process has not been completed.

15. BIOLOGICAL ASSETS

None.

16. PREPAID EXPENSES AND DEFERRED INCOME

Short Term Prepaid Expenses

	December 31, 2014	December 31, 2013
Advances Given to Related Parties	-	22.664
Advances Given to Other Parties	13.532.203	8.319.869
Insurance Expenses	432.870	233.912
Rent Expenses	159.237	65.588
Subscription Expenses	5.908	-
Service Expenses	9.096	6.011
Maintenance and Repair Expenses	1.158	3.152
	14.140.472	8.651.196

Long Term Prepaid Expenses

	December 31, 2014	December 31, 2013
Subscription Expenses	1.502	-
	1.502	-

Deferred Income

None.

17. RECEIVABLES FROM ONGOING CONSTRUCTION CONTRACTS

None.

18. INVESTMENTS VALUED BY EQUITY METHOD

Associates	%	December 31, 2014	%	December 31, 2013
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	17	4.256.112	17	4.250.000

17% of the shares of Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş. were purchased by The Company on March 28, 2013.

According to fifth matter of TAS 28 "Investments in Associates", if an investor holds, directly or indirectly (eg through subsidiaries), 20% or more of the voting power of the investee, it is presumed that the investor has significant influence, unless it can be clearly demonstrated that this is not the case. Conversely, according to sixth matter if the investor holds, directly or indirectly (eg through subsidiaries), less than 20% of the voting power of the investee, it is presumed that the investor does not have significant influence, unless such influence can be clearly demonstrated. The

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

existence of significant influence by an investor is usually evidenced in one or more of the following ways:(a) representation on the board of directors or equivalent governing body of the investee; (b) participation in policy-making processes, including participation in decisions about dividends or other distributions; (c) material transactions between the investor and the investee; (d) interchange of managerial personnel; or (e) provision of essential technical information. According to this, even though The Company has 17% of Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş., it is considered as The Company has significant influence while the conditions in sixth matter is fulfilled.

Associates	Goodwill*	Cost	Acquisition Cost
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	3.910.000	340.000	4.250.000

*According to thirtysecond matter of TAS 28 “Investments in Associates”, an investment in an associate is accounted for using the equity method from the date on which it becomes an associate. Goodwill related to an associate is added to book value of associate investment. According to this, 3,910.000-TL goodwill is included to the book value of associates, other than 340.000-TL associate share related with Sasbaş Samsun Serbest Bölgesi Kurucusu ve İşleticisi A.Ş..

According to equity method, investments in associates are recorded by acquisition cost in the beginning. After acquisition, book value of the investment is increased or decreased in order to recognise the share of the investor in the invested company’s profit/loss. The share which investor will get from invested company’s profit/loss is recognised as investor’s profit/loss.

As of December 31, 2014, 323.509-TL share from associates’ profit increases the book value of associates and also is recognised as shares of investments evaluated by equity method in profit/(loss) in profit or loss statement.

The detail of the change in Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.’s value for the period between January 1, 2013 – December 31, 2014 is as follows:

	January 1- December 31, 2014
Acquisition Cost	4.250.000
The Share from Associate’s Profit/Loss as of December 31, 2013*	136.737
The Share from Associate’s Profit/Loss as of December 31, 2014*	186.772
Accrued Dividend Yield	(317.397)
	4.256.112

*Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş. is recognised by its cost value in the financial statements as of December 31, 2013. Shares of investments evaluated by equity method in the financial statements as of December 31, 2014, is reflected to profit or loss statement as 323.509-TL, which is the sum of 136.737-TL share of The Company from Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.’s profit as of December 31, 2013 and 186.772-TL share of The Company from Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.’s profit as of December 31, 2014.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

According to TFRS 12 “Disclosure of Interests in Other Entities” B12 (a) and (b) matters; disclosure requirements for summarised financial information as of December 31, 2014 and December 31, 2013 is as follows*:

	December 31, 2014	December 31, 2013
Current Assets	605.347	1.023.468
Non-Current Assets	4.829.790	5.143.501
Short Term Liabilities	139.840	147.075
Long Term Liabilities	236.037	192.254
Revenue	3.139.275	2.415.416
Continuing Profit/(Loss) for the Period	1.098.660	804.333
The Period Profit/(Loss) After Tax for Discontinued Operations	-	-
Other Comprehensive Income	1.098.660	804.333
Total Comprehensive Income	1.098.660	804.333
Dividend Yield Acquired	-	-

* According to B15 (b) matter of TFRS 12 “Disclosure of Interests in Other Entities”; financial information is obtained from associate’s legal accounting records.

19. INVESTMENT PROPERTIES

None.

20. CORPORATE TAX ASSETS

	December 31, 2014	December 31, 2013
Prepaid Taxes and Funds	374.740	-

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014
(Amounts expressed in TL, unless otherwise is stated.)

21. TANGIBLE ASSETS

Detail of the tangible assets as of December 31, 2014 is as follows:

Acquisition Cost	Plant Machinery and Equipment	Underground and Overland Plants	Land	Buildings	Furniture and Fixtures	Vehicles	Leasehold Improvements	Constructions In Progress	Total
January 1, 2014 Opening Balance	16.289.601	216.221	14.336.515	17.044.280	708.135	3.963.151	-	430.754	52.988.657
Additions	987.551	-	-	-	207.171	1.315.157	383.467	373.665	3.267.011
Disposals	(42.160)	-	-	-	-	(527.645)	-	-	(569.805)
Reclassification	10.819	-	-	71.596	-	-	-	(82.415)	-
December 31, 2014 Closing Balance	17.245.811	216.221	14.336.515	17.115.876	915.306	4.750.663	383.467	722.004	55.685.863

Accumulated Depreciation	Plant Machinery and Equipment	Underground and Overland Plants	Land	Buildings	Furniture and Fixtures	Vehicles	Leasehold Improvements	Constructions In Progress	Total
January 1, 2014 Opening Balance	4.386.162	38.220	-	611.803	462.770	1.253.522	-	-	6.752.477
Charge for the Period	645.597	5.232	-	434.996	81.919	435.244	8.414	-	1.611.402
Disposals	(1.471)	-	-	-	-	(201.243)	-	-	(202.714)
Reclassification	-	-	-	-	-	-	-	-	-
December 31, 2014 Closing Balance	5.030.288	43.452	-	1.046.799	544.689	1.487.523	8.414	-	8.161.165

Net Book Value (As of December 31, 2014)	12.215.523	172.769	14.336.515	16.069.077	370.617	3.263.140	375.053	722.004	47.524.698
---	-------------------	----------------	-------------------	-------------------	----------------	------------------	----------------	----------------	-------------------

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014
(Amounts expressed in TL, unless otherwise is stated.)

Detail of the tangible assets as of December 31, 2013 is as follows:

Acquisition Cost	Plant Machinery and Equipment	Underground and Overland Plants	Land	Buildings	Furniture and Fixtures	Vehicles	Constructions In Progress	Total
January 1, 2013 Opening Balance	13.124.673	114.135	3.528.593	3.925.899	622.330	3.992.175	230.915	25.538.720
Additions	534.392	4.112	-	-	87.506	356.509	199.839	1.182.358
Disposals	-	-	-	-	(1.701)	(385.533)	-	(387.234)
Tangible Asset Revaluation*	-	-	13.391.486	13.263.327	-	-	-	26.654.813
Reclassification	2.630.536	97.974	(2.583.564)	(144.946)	-	-	-	-
December 31, 2013 Closing Balance	16.289.601	216.221	14.336.515	17.044.280	708.135	3.963.151	430.754	52.988.657

Plant Machinery and Equipment	Plant Machinery and Equipment	Underground and Overland Plants	Land	Buildings	Furniture and Fixtures	Vehicles	Constructions In Progress	Total
January 1, 2013 Opening Balance	3.268.381	6.395	-	907.404	408.189	915.956	-	5.506.325
Charge for the Period	608.913	5.196	-	239.896	54.947	464.021	-	1.372.973
Disposals	-	-	-	-	(366)	(126.455)	-	(126.821)
Reclassification	508.868	26.629	-	(535.497)	-	-	-	-
December 31, 2013 Closing Balance	4.386.162	38.220	-	611.803	462.770	1.253.522	-	6.752.477

Net Book Value (As of December 31, 2013)	11.903.439	178.001	14.336.515	16.432.477	245.365	2.709.629	430.754	46.236.180
---	-------------------	----------------	-------------------	-------------------	----------------	------------------	----------------	-------------------

*As a result of revaluation of lands and buildings, 26.654.813-TL total revaluation fund is realised (Vide Note 29).

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Construction plan/expropriation work information and lien inspection related with the real estates of The Company as of December 31, 2014 are as follows:

SQUARE 349; PARCEL NO 17

Construction Plan/Expropriation Work Info

Square 349, parcel no 17 is in the Industrial Area due to construction plan.

SQUARE 496; PARCEL NO 6 , SQUARE 499; PARCEL NO 6, PARCEL NO 14, PARCEL NO 15, PARCEL NO 16, PARCEL NO 17, PARCEL NO 18, PARCEL NO 19, PARCEL NO 20, PARCEL NO 22, PARCEL NO 27

Construction Plan/Expropriation Work Information

Square 496; parcel no 6 is in Housing Area.

Square 499; parcel no 3 is in Non-residential Urban Work Area

Square 499; parcel no 14, 15, 16, 17, 18, 19, 20, 22 and 27 are in Housing Area.

SQUARE 511; PARCEL NO 1 and PARCEL NO 8

Construction Plan/Expropriation Work Information

Square 511; parcel no 1 and 8, are in the Industrial Area.

Liens related with square 511; parcel no 1 are as follows:

6,47 m² of this parcel rapes the road and 24,68m² rapes square 511 parcel no 7.

In a part of 360,34m² there is easement in favor of M. TEK General Management.

Liens related with square 511; parcel no 8 are as follows:

Square 511, parcel no 7 has a breach of 480,53 m² on this parcel. This parcel has a breach of 35,70 m² on square 511, parcel no 7.

SQUARE 681; PARCEL NO 33 AND 37

Square 681, parcel no 33 and 37 are in the Park and Inappropriate Geologic Area.

Square 681, parcel no 33 and 37 are completely in Park and Inappropriate Geologic Area. Therefore it is estimated that they will be expropriated as a result of bringing Expropriation Law numbered 2942 in to action.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

22. INTANGIBLE ASSETS

Goodwill

None.

Other Intangible Assets

Detail of the intangible assets as of December 31, 2014 is as follows:

Acquisition Cost	Rights (Computer Programs)	Total
January 1, 2014 Opening Balance	122.912	122.912
Additions	12.755	12.755
Disposals	-	-
Reclassification	-	-
December 31, 2014 Closing Balance	135.667	135.667

Accumulated Depreciation	Rights (Computer Programs)	Total
January 1, 2014 Opening Balance	73.424	73.424
Charge for the Period	12.109	12.109
Disposals	-	-
Reclassification	-	-
December 31, 2014 Closing Balance	85.533	85.533

Net Book Value (As of December 31, 2014) 50.134 50.134

Detail of the intangible assets as of December 31, 2013 is as follows:

Acquisition Cost	Rights (Computer Programs)	Total
January 1, 2013 Opening Balance	100.731	100.731
Additions	22.181	22.181
Disposals	-	-
Reclassification	-	-
December 31, 2013 Closing Balance	122.912	122.912

Accumulated Depreciation	Rights (Computer Programs)	Total
January 1, 2013 Opening Balance	62.419	62.419
Charge for the Period	11.005	11.005
Disposals	-	-
Reclassification	-	-
December 31, 2013 Closing Balance	73.424	73.424

Net Book Value (As of December 31, 2013) 49.488 49.488

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

23. GOVERNMENT GRANTS AND INCENTIVES

Government grants consist of Social Security Institution Premium Fund due to law numbered 5510.

24. PROVISIONS, CONTINGENT ASSETS AND LIABILITIES

Short Term Provisions

None.

Long Term Provisions

	December 31, 2014	December 31, 2013
Long Term Provisions for Employee Benefits*	607.917	543.165
Other long Term Provisions	-	-
	607.917	543.165

*(Vide note 26)

Lawsuits

There is not any provision because there is not any possible cash outflow from The Company's liabilities as a result of previous events as of reporting date.

Pledges, Assurance and Pawn (PAP) Given by The Company

	December 31, 2014*	December 31, 2013*
A. Total Amount of PAP Given by The Company's Own Legal Personality	23.277.797	8.648.515
B. Total Amount of PAP Given In Favour of Fully Consolidated Companies	-	-
C. Total Amount of PAP Given For Continuation of Its Economic Activities on Behalf of Third Parties	-	-
D. Total Amount of Other PAP	-	-
i. Total Amount of PAP Given in Favour of Majority Shareholder	-	-
ii. Total Amount of PAP Is Given in Favour of Other Group Companies Which Are Not In the Scope of B and C	-	-
iii. Total Amount of PAP is Given in Favour of Third Parties Which Are Not In the Scope of C	-	-
Total	23.277.797	8.648.515

The Company's total guarantee in banks is 344.745.030 TL as of December 31, 2014.
(December 31, 2013:90.332.750-TL)

* There is not any pawn upon The Company's fixed assets.

25. COMMITMENTS

None.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

26. EMPLOYEE BENEFITS

Payables Related with Employee Benefits

Details of payables related with employee benefits as of December 31, 2014 and December 31, 2013 are:

	December 31, 2014	December 31, 2013
Social Security Institution Premiums	118.895	92.314
Due to Personnel	268.797	209.629
	387.692	301.943

Short Term Employee Benefits

Short term employee benefits are consist of provision for unused vacation.

Details of short term employee benefits as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Provision for Unused Vacation	-	-

Long Term Employee Benefits

Long term employee benefits are consist of provision for employee termination benefits.

According to Turkish Laws, employer has to pay employee termination benefit to employee who has worked at least a year in local firms, and whose employment is terminated without a legitimate reason, who is called for military obligation, who dies, who works for 25 years for males, 20 years for females, or who is 60-year-old male and 58-year-old female (retirement age).

As of December 31, 2014 provision for employee termination benefit ceiling on the respective balance sheet dates, is subject to a maximum of 3.438,22-TL per month for a working year (December 31, 2013: 3.254,44 -TL).

Provision for employee termination benefits is not subordinated any fund.

Provision for employee termination benefits is calculated by discounting potential liabilities of retirement to net present value. TFRS requires companies to improve actuarial valuation methods in the scope of retirement plans in order to estimate the termination benefits. Therefore, below mentioned actuarial estimations are used in order to calculate total employee termination benefits.

Provisions for employee termination is calculated by the discount rate of 1,78%, which is determined by 6% inflation rate and 7,89% interest rate. The release rate is 96% (December 31, 2013: inflation rate 5% , interest rate 8% and discount rate 2,86% , release rate 97%).

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Details of the provision for employee termination benefits as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Provision for Employee Termination Benefits	607.917	543.165

Details of provision for employee termination benefits are as follows:

	December 31, 2014	December 31, 2013
Opening Balance	543.165	497.529
Interest Cost	28.992	26.381
Service Cost	93.943	88.286
Payments (-)	(82.098)	(104.365)
Actuarial Differences	23.915	35.334
Closing Balance	607.917	543.165

Changes in interest rates and other rates and severance of personnel who are supposed to get compensation at retirement cause actuarial differences. The Company classifies service cost in general administrative expenses, interest costs in financial expenses, actuarial differences in shareholders' equity.

27. RETIREMENT BENEFITS

None.

28. OTHER ASSETS AND OTHER LIABILITIES

Other Current Assets

	December 31, 2014	December 31, 2013
Deferred VAT	2.586.671	1.564.852
Other VAT	3.951	-
Business Advances	-	-
	2.590.622	1.564.852

Other Short Term Liabilities

	December 31, 2014	December 31, 2013
Advances Received from Related Parties	6.432	-
Advances Received from Other Parties	11.086.487	3.174.364
Taxes and Funds Payables	106.584	94.357
	11.199.503	3.268.721

Other Non-Current Assets

None.

Other Long Term Liabilities

None.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

29. EQUITY

Capital and Reserves

The issued capital of The Company was increased to 65.000.000-TL in the General Assembly on March 20, 2014. 3.357.865,93-TL of the 15.000.000-TL increased capital is cash, 6.642.206,26-TL is from accumulated profit and 4.999.927,81-TL is from special funds.

In the meeting dated November 7, 2014 and numbered 32/1095, CMB has allowed The Company to public offer on November 12-13-14, 2014 by book building (demand gathering) method. Total of 23.500.000 TL nominal value shares, which were offered to public by capital increase and sales of shareholders, were sold. 27,81% of The Company shares has been traded in Borsa İstanbul since November 20, 2014. The issued capital of The Company is 84.500.000 TL (Eightyfourmillion and fivehundredthousand Turkish Lira). This capital consists of 9.750.000 Group A shares, 6.500.000 Group B shares and 68.250.000 Group C shares and each worths 1,00TL that makes a total of 84.500.000 TL. Group A and B shares are registered to the name and Group C shares which are traded in Borsa Istanbul are registered to the bearer, other Group C shares are registered to the name. Group A shares have privilege to vote in the election of Board of Directors, Group A and B shares have privilege to vote in General Assembly and not considering independent members, in case the Board of Directors consist of five members, at least two members, in case it consists of six or seven members, at least three members, in case it consists of eight or nine members, at least four members, in case it consists of ten or eleven members, at least five members must be chosen among the candidates who are nominated by the majority of Group A shareholders. Group A shareholders or representatives have 15 votes, Group B shareholders or representatives have 10 votes, Group C shareholders or representatives have 1 vote for each share in the ordinary or extraordinary General Assembly.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Shareholder structure of The Company as of December 31, 2014 is as follows:

Shareholders	Number Of Shares	Group	Rate (%)	Amount
Fahrettin Ulusoy	4.550.000	A	5,38	4.550.000
	1.950.000	B	2,31	1.950.000
	23.873.882	C	28,25	23.873.882
	30.373.882		35,94	30.373.882
Nevin Ulusoy	650.000	A	0,77	650.000
	1.300.000	B	1,54	1.300.000
	5.830.756	C	6,90	5.830.756
	7.780.756		9,21	7.780.756
Onur Erhan Ulusoy	650.000	A	0,77	650.000
	1.950.000	B	2,31	1.950.000
	7.423.684	C	8,78	7.423.684
	10.023.684		11,86	10.023.684
Eren Günhan Ulusoy	3.900.000	A	4,62	3.900.000
	1.300.000	B	1,54	1.300.000
	7.499.375	C	8,88	7.499.375
	12.699.375		15,04	12.699.375
Kamil Adem	26.941	C	0,03	26.941
	26.941		0,03	26.941
Mithat Denizcigil	95.362	C	0,11	95.362
	95.362		0,11	95.362
Public Shares	23.500.000	C	27,81	23.500.000
	84.500.000		100,00	84.500.000

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Shareholder structure of The Company as of December 31, 2013 is as follows:

Shareholders	Number Of Shares	Group	Rate (%)	Amount
Fahrettin Ulusoy	3.500.000	A	7,00	3.500.000
	1.500.000	B	3,00	1.500.000
	21.441.448	C	42,88	21.441.448
	26.441.448		52,88	26.441.448
Nevin Ulusoy	500.000	A	1,00	500.000
	1.000.000	B	2,00	1.000.000
	4.485.197	C	8,97	4.485.197
	5.985.197		11,97	5.985.197
Onur Erhan Ulusoy	500.000	A	1,00	500.000
	1.500.000	B	3,00	1.500.000
	5.710.526	C	11,42	5.710.526
	7.710.526		15,42	7.710.526
Eren Günhan Ulusoy	3.000.000	A	6,00	3.000.000
	1.000.000	B	2,00	1.000.000
	5.768.750	C	11,54	5.768.750
	9.768.750		19,54	9.768.750
Kamil Adem	20.724	C	0,04	20.724
	20.724		0,04	20.724
Mithat Denizcigil	73.355	C	0,15	73.355
	73.355		0,15	73.355
	50.000.000		100,00	50.000.000

According to Turkish Commercial Code, there are two types of legal reserves; primary reserves and secondary reserves. Primary reserves are set up as 5% of the net profit until it reaches 20% of The Company's paid-in-capital due to Turkish Commercial Code. Secondary legal reserves are set up as 1/11 proportion of distribution of dividends by cash which is more than 5% of The Company's capital according to CMB's regulation, and 1/10 proportion of distribution of dividends by cash which is more than 5% of The Company's capital according to official records.

Publicly traded companies distribute dividends according to the II-19.1 numbered Dividend Communique of CMB which is published in January 23, 2014 dated and 28891 numbered Official Gazette.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Companies distribute dividends by a decree of their general assembly in the scope of the determined policy of their general assembly and due to the related regulations. According to the mentioned communique of CMB, minimum distribution ratio has not been determined. Companies distribute dividends according to their articles of association or their dividend policy. Also dividends can be paid by equal or different amounting installments and dividend advances can be paid by cash due to the profit in interim financial statements.

In case the contingency reserves are not allocated according to Turkish Trade Regulation and profit is not distributed as mentioned in the dividend policy or articles of association; it is not allowed to allocate another contingency reserve to transfer profit to the following year and to distribute dividends to beneficial owners, board members, employees and people other than shareholders, and also dividends can not be paid to these people unless dividends are not paid to the shareholders by cash.

	December 31, 2014	December 31, 2013
Share Premiums on Capital Stock	41.925.000	-
Expenses of Share Premiums on Capital Stock Expenses (-)	(3.317.008)	-
	38.607.992	-

According to thirteenth matter of TAS 32 "Financial Instruments", The Company bears some expenses while issuing or repurchasing equity instruments. These expenses may contain registration and other regulatory charges, legal, financial and other professional consulting fees, printing costs and stamp tax duties. Transaction costs of equity transactions are recognised as deduction from equity as long as they are directly incurred additional costs as a result of these transactions. Additionally, costs related with cancelled equity transactions are recognised as expenses.

Additional expenses, related with the issuance of new share certificates directly (indirectly), are deducted from equity after related taxes are deducted from these expenses. Expenses related with the permission for trading in stock market (quotation) or expenses that are not directly related with the issuance of new stocks are recognised as expenses in profit and loss statement. Expenses related with the permission for either flotation in stock market or quotation are allocated due to the proportion of shares that are offered between two transactions.

Other Equity Items

Other accumulated comprehensive income and expenses which are not classified in profit/loss as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Tangible Assets Revaluation Differences	21.763.600	21.905.713
Actuarial Profit/Loss Related with the Employee Benefits*	(47.399)	(28.267)
	21.716.201	21.877.446

*Actuarial differences have been recognised in equity since January 1, 2013.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Details of the actuarial differences as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Actuarial Gains/(Losses) Related with the Employee Benefits	(59.249)	(35.334)
Deferred Tax***	11.850	7.067
Actuarial Gains/(Losses) Related to Employee Benefits (net)	(47.399)	(28.267)

Details of tangible assets revaluation fund as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Revaluation Differences of Buildings and Lands (net)	21.323.851	21.323.851
Revaluation Differences of Vehicles (net)	439.749	581.862
	21.763.600	21.905.713

Detail of the revaluation differences of lands and buildings as of December 31, 2014 and December 31, 2013 is as follows:

	December 31, 2014	December 31, 2013
Total Lands and Buildings Revaluation Difference **	26.654.813	26.654.813
Deferred Tax ***	(5.330.962)	(5.330.962)
Revaluation Differences of Buildings and Lands (net)	21.323.851	21.323.851

** Valuation of the buildings in The Company's assets was realised by Standart Gayrimenkul Değerleme Uygulamaları A.Ş. on June 28, 2013. Current values are determined by reference comparison, decomposition and income capitalization methods. According to cost method, total net book value of lands and buildings of The Company is 4.188.988-TL. Total value after valuation including land and building share is 30.405.592-TL.

Details of the vehicles revaluation fund as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Vehicles Revaluation Differences (net)	439.749	581.862

	December 31, 2014	December 31, 2013
Total Vehicle Revaluation Differences ****	549.686	727.327
Deferred Tax ***	(109.937)	(145.465)
	439.749	581.862

**** Valuation of vehicles was realised by Erçal Otomotiv Sanayi Ticaret Limited Şirketi and Felek Otomotiv Sanayi Ticaret Ltd. Şti. on December 26, 2012. Market prices were determined according to the local market values. The lowest value found was used for the valuation. 799.913-TL revaluation difference and 112.881-TL valuation expense are realised by the study. As of December 31, 2014 gross value according to cost model is 4.309.024-TL, total accumulated depreciation is 1.458.388-TL and net book value is 2.850.636-TL. In 2014, the vehicle which was revaluated and of which revaluated cost value was 527.645-TL has been sold. Gross revaluation fund of the sold vehicle is 177.651-TL, deferred tax effect is 35.528-TL and net revaluation fund is 142.123-TL.

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

***According to TAS 12, 61-a, current tax and deferred tax related with the items which are not recognised in profit or loss, are not recognised in profit or loss both in the same or different period. Therefore, current tax and deferred tax that are related with the items that are recognised in the same or different period in other comprehensive income shall be recognised in other comprehensive income. Realised deferred tax is classified in revaluation fund.

The Company's restricted reserves as of December 31, 2014 and December 31, 2013 are as follows:

	December 31, 2014	December 31, 2013
Legal Reserves	1.400.369	1.050.779

Accumulated profit or loss as of December 31, 2014 and December 31, 2013 is as follows:

	December 31, 2014	December 31, 2013
Accumulated Profit/(Loss)	2.474.682	1.415.578

Detail of Accumulated Profit/(Loss) is as follows:

	December 31, 2014
Accumulated Profit/(Loss) for 2013 Year	1.415.578
Transfer of Profit for 2013 Year to the Accumulated Profit/(Loss)	7.699.189
Capital Contribution	(6.642.206)
Adjustment*****	2.121
	2.474.682

***** Consists of adjustments related to corporate tax.

Net profit/(loss) for the period as of December 31, 2014 and December 31, 2013 are as follow:

	December 31, 2014	December 31, 2013
Net Profit/(Loss) For The Period	14.189.389	8.048.779

30. REVENUE AND COST OF SALES

Details of revenue as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Domestic Sales	543.370.137	412.376.857
Foreign Sales	380.550.059	270.961.061
Sales Returns (-)	(2.057.438)	(578.846)
Sales Discounts (-)	(285.393)	(581.713)
Other Discounts (-)	-	(14.016)
	921.577.365	682.163.343

Details of cost of sales as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Cost of Goods Sold	190.399.453	165.596.616
Cost of Merchandise Sold	671.793.450	468.186.950
	862.192.903	633.783.566

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

31. GENERAL ADMINISTRATIVE EXPENSES, MARKETING EXPENSES, RESEARCH AND DEVELOPMENT EXPENSES

Details of total operating expenses as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
General Administrative Expenses	5.234.767	4.253.659
Marketing Expenses	20.335.403	17.759.151
Research and Development Expenses	-	-
	25.570.170	22.012.810

Details of General Administrative Expenses as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Depreciation Expenses	102.442	65.951
Vehicle Expenses	240.154	174.820
Grants and Aids	109.543	161.801
Maintenance and Repair Expenses	13.932	89.408
Bank Transfer and Collecting Expenses	-	44.110
Consultancy Expenses	342.188	266.617
Outsourced Benefits and Services	772.947	534.639
Other Expenses	463.448	227.468
Education and Publication Expenses	39.512	2.073
Exposition Expenses	33.785	36.815
Late Fees and Charges	7.323	74.790
Heat and Water Expenses	8.255	7.987
Provision for Employee Termination Benefits Expenses	93.943	88.286
Rent Expenses	100.373	20.492
Accommodation Expenses	-	45.694
Court Expenses	-	3.481
Brand, Apl. and Ren. of Patent Expenses	10.801	27.819
Notary Expenses	-	31.333
Personnel Expenses	2.119.688	1.949.741
Advertising Expenses	-	4.290
Insurance Expenses	-	14.544
Registration and Announcement Expenses	-	13.770
Transportation Expenses	118.731	106.632
Taxes and Funds	101.899	214.696
Food Expenses	34.968	46.402
Public Offering Expenses	463.598	-
Health Expenses	18.555	-
Commission Expenses	38.682	-
General Administrative Expenses	5.234.767	4.253.659

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Details of Marketing Expenses as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Depreciation Expenses	435.244	464.021
Vehicle Expenses	2.215.294	1.798.860
Maintenance and Repair Expenses	-	2.041
Bank Transfer and Collecting Expenses	-	39.250
Consultancy Expenses	75.289	65.646
Outsourced Benefits and Services	577.925	94.676
Other Expenses	92.288	389.289
Exposition Expenses	64.766	112.300
Late Fees and Charges	16.414	23.333
Export Expenses	1.614.890	844.112
Rent Expenses	172.602	8.286
Sales Commissions Expenses	213.518	245.343
Accommodation Expenses	-	60.709
Court Costs	-	221
Freight Expenses	13.993.777	12.314.144
Notary Expenses	-	944
Personnel Expenses	579.923	367.889
Advertising Expenses	-	80.986
Insurance Expenses	-	146.883
Terminal Expenses	-	363.483
Registration and Announcement Expenses	-	152.823
Transportation Expenses	41.258	36.658
Taxes and Funds	145.195	63.652
Food Expenses	97.020	83.602
Marketing Expenses	20.335.403	17.759.151

Nature of expenses for the period January 1, 2014 – December 31, 2014 is as follows:

	General Administrative Expenses	Marketing Expenses	Research and Development Expenses	Cost of Sales
Personnel Expenses	2.119.688	579.923	-	2.630.984
Depreciation Expenses	102.442	435.244	-	1.085.825

Nature of expenses for the period January 1, 2013 – December 31, 2013 is as follows:

	General Administrative Expenses	Marketing Expenses	Research and Development Expenses	Cost of Sales
Personnel Expenses	1.949.741	367.889	-	2.268.947
Depreciation Expenses	65.951	464.021	-	854.006

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

32. OTHER INCOME AND OTHER EXPENSES

Other Income

	January 1- December 31, 2014	January 1- December 31, 2013
Income Due to the Law No 5510	189.340	163.962
Allocated Balance Income	72.082	67.418
Other Income	152.218	93.190
Service Reflection Income*	3.248.294	1.911.552
Discount Income	-	136.892
Rental Income	-	1.000
Insurance Income	427.660	622.854
Sales of Fixed Assets	134.046	230.271
Provisions No Longer Required	156.864	393.962
Income From Returned Expenses	289.053	375.402
Income from Indemnity	140.396	-
Income From Incentive and Support	-	96.323
Inventory Difference	-	631.418
Financial Asset Sale Income	-	650.000
	4.809.953	5.374.244

*Service reflection income consists of reflection revenues of trust expenses and, reflection revenues of service expenses.

Other Expenses

	January 1- December 31, 2014	January 1- December 31, 2013
Trust Expenses	1.924.087	1.695.928
Other Expenses	30.979	276.176
Balance Dedication Expenses	103.103	147.593
Provision Expenses	1.365.082	480.134
Impairment of Fixed Assets	-	162.294
Returned Expenses	228.427	154.162
Public Offering Reflection Expenses	121.936	-
	3.773.614	2.916.287

33. SHARES OF INVESTMENTS EVALUATED BY EQUITY METHOD IN PROFIT/LOSS

Details of profit/loss shares of investments evaluated by equity method as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.*	323.509	-

*(Vide note 18)

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

34. FINANCIAL INCOME AND EXPENSES

Financial Income

	January 1- December 31, 2014	January 1- December 31, 2013
Interest Income	4.357.650	1.590.442
Foreign Currency Gains	58.715.730	31.384.436
Deferred Interest Income	11.593.257	9.417.832
Derivative Financial Instruments Income	9.057.826	7.351.990
Security Sales Income	185.521	-
Derivative Financial Instruments Fair Value Difference	2.285.089	-
	86.195.073	49.744.700

Financial Expenses

	January 1- December 31, 2014	January 1- December 31, 2013
Foreign Currency Expenses	70.921.037	46.278.583
Financial Expenses	7.397.291	7.537.183
Security Sales Losses	19.847	-
Deferred Interest Expenses	17.540.193	7.543.741
Derivative Financial Instruments Expenses	7.943.816	6.577.681
	103.822.184	67.937.188

35. FIXED ASSETS HELD FOR SALE AND CEASED OPERATIONS

None.

36. TAX ASSETS AND TAX LIABILITIES

Corporation tax is charged from taxable corporate income, which is calculated from the statutory accounting profit by adding non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

In 2014 corporate tax rate is 20% (2013: 20%).

In Turkey pre-paid corporate tax is calculated and accrued quarterly. In 2014, pre-paid corporate tax rate is 20% of the corporation income for the quarterly taxation periods (2013: 20%).

Losses can be carried forward to offset from future taxable income for up to 5 years. Losses cannot be carried back to offset from profit of the previous periods.

There is not a specific procedure for a final and definitive agreement on tax assessments in Turkey. Companies prepare their current year tax returns within April 1-25 of the following year (The duration for the companies which has private fiscal year between 1st and the 25th day of the forth month following the closing date of the fiscal year). Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years.

Income Withholding Tax:

In addition to corporate taxes, companies should also calculate income withholding taxes and funds surcharge on any dividends distributed, except for companies receiving dividends who are resident

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

companies in Turkey and Turkish branches of foreign companies. The rate of income withholding tax is 10% beginning from April 24, 2003. This rate modified to 15% by the law No: 5520, article 15 valid from June 21, 2006. However, by the new cabinet decision the rate was stated to be 10% until it is modified. The income withholding tax becomes 15% by publishing on the official journal by the cabinet decision on July 23, 2006. Undistributed dividends incorporated in share capital are not subject to income withholding taxes.

Deferred Tax Assets / Liability:

The Company recognises deferred tax assets and liabilities based upon temporary differences arising from differences between its financial statements as reported based on the "Financial Reporting Standards in capital market" and its statutory tax financial statements. These differences are set out below. Deferred tax asset is only provided to the extent if it is probable that taxable profit will be available against which the deductible temporary differences can be utilized. Provision is provided for the deferred tax asset of which the realisation is not likely. Deferred tax rate is 20% for all temporary differences since there is investment incentive of The Company (December 31, 2013: 20%).

Deferred tax liabilities are recognised for all taxable temporary differences.

Temporary difference and deferred tax as of December 31, 2014 are as follows:

Deferred Tax Assets	Temporary Difference	Deferred Tax
Loan Expenses	16.989	3.398
Doubtful Trade Receivables	3.160.671	632.133
Adjustment on Receivables from Personnel	68.895	13.779
Adjustment on Inventory Differences	216.652	43.330
Adjustment on Advances Given	153.939	30.788
Adjustment on Letter of Credit Interest	963	193
Impairment of Inventories Expenses	117.649	23.530
Adjustment on Amortized Cost of Receivables	1.275.218	255.043
Adjustment on Tangible and Intangible Assets	194.487	38.897
Adjustment on Amortized Cost of Payables	1.704.803	340.960
Adjustment on Warehouse Expenses	286.038	57.208
Constructions in Progress	17.970	3.594
Actuarial Difference of Employee Termination Benefits *	59.249	11.850
Adjustment on Financial Assets	165	33
	7.273.688	1.454.736

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Deferred Tax Liabilities	Temporary Difference	Deferred Tax
Vehicles Revaluation Difference (Related with Equity)	549.686	109.937
Lands and Buildings Revaluation Difference (Related with Equity)	26.654.813	5.330.962
Adjustment on Bank Interest Income Accruals	128.502	25.700
Adjustment on Cost of Inventories	305.452	61.090
Adjustment on Derivative Financial Instruments Income	2.285.089	457.018
Tangible and Intangible Assets Depreciation Difference	5.054.396	1.010.880
Employee Termination Benefits Actuarial Difference*	1.142.537	228.507
Adjustment on Other Payables	1.976	395
	36.122.451	7.224.489

Temporary difference and deferred tax as of December 31, 2013 are as follows:

Deferred Tax Assets	Temporary Difference	Deferred Tax
Amortized Cost of Receivables and Payables	833.494	166.699
Tangible and Intangible Assets Depreciation Difference	46.752	9.350
Fixed Assets Under Construction	8.985	1.797
Derivative Financial Instruments	774.309	154.862
Severance Pay Actuarial Difference*	35.334	7.067
Other	68.895	13.779
Loans	190.787	38.158
Tangible Assets Sale	157.461	31.492
	2.116.017	423.204

Deferred Tax Liabilities	Temporary Difference	Deferred Tax
Doubtful Trade Receivables	303.883	60.777
Provision for Financial Assets Impairment Loss	1.040.000	208.000
Letters of Credit Interest	1.346.633	269.327
Loan Expenses	38.960	7.793
Lands and Buildings Revaluation Difference (Related to Equity)	26.654.813	5.330.962
Provisions For Employee Termination Benefits	227.477	45.495
Vehicles Revaluation Difference (Related to Equity)	727.327	145.465
	30.339.093	6.067.819

Changes in the deferred tax as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Opening Balance	(175.255)	416.220
Deferred Tax Income /(Expenses) for The Period	(165.449)	(591.475)
Tangible Assets Revaluation Fund and Actuarial Difference		
Deferred Tax Effect*	(5.429.049)	(5.469.360)
Closing Balance	(5.769.753)	(5.644.615)

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

*According to TAS 12, 61-a, current tax and deferred tax related with the items which are not recognised in profit or loss, are not recognised in profit or loss both in the same or different period. Therefore, current tax and deferred tax that relates to items that are recognised, in the same or a different period in other comprehensive income, shall be recognised in other comprehensive income. Deferred tax liability which is calculated by actuarial differences, is recognised in other comprehensive income.

Tax expenses as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Current Period Tax Income/(Expenses)	3.192.191	1.992.182
Deferred Tax(Profit)/ Loss	165.449	591.475
	3.357.640	2.583.657

Tax provisions as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Corporate Tax Liabilities	3.192.191	1.992.182
Prepaid Taxes and Funds	(2.166.036)	(1.849.716)
	1.026.155	142.466

37. EARNINGS PER SHARE

Details of earning per share as of December 31, 2014 and December 31, 2013 are as follows:

	January 1- December 31, 2014	January 1- December 31, 2013
Net Profit/(Loss) for the Period	14.189.389	8.048.779
Number of Ordinary Shares	84.500.000	50.000.000
Earnings Per Share	0,1679	0,1609

38. RELATED PARTY DISCLOSURES

	January 1- December 31, 2014	January 1- December 31, 2013
Unay Un San. ve Tic. A.Ş.	1.831.879	379.459
Notes Receivable from Related Parties	1.831.879	379.459

	January 1- December 31, 2014	January 1- December 31, 2013
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	-	600
GK Tarım Ürünleri Depoculuk A.Ş.	-	511.444
Other Receivables from Related Parties	-	512.044

	January 1- December 31, 2014	January 1- December 31, 2013
Ulusoy Petrol Ürünleri Tic. A.Ş.	-	22.664
Prepaid Expenses to Related Parties	-	22.664

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

	January 1- December 31, 2014	January 1- December 31, 2013
Eren Günhan Ulusoy	-	958
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	277.569	350.579
Ulusoy Petrol Ürünleri Tic. A.Ş.	37.566	-
Kamil Adem	-	8.635
Trade Payables to Related Parties	315.135	360.172
	January 1- December 31, 2014	January 1- December 31, 2013
Unay Un San. ve Tic. A.Ş.	2.027.734	1.104.795
Notes Payable to Related Parties	2.027.734	1.104.795
	January 1- December 31, 2014	January 1- December 31, 2013
Ulusoy Çay Gıda San. ve Tic. A.Ş.	6.432	-
Advances Taken from Related Parties	6.432	-
	January 1- December 31, 2014	January 1- December 31, 2014
Unay Un San. ve Tic. A.Ş.		19.487.389
Sales to Related Parties		19.487.389
	January 1- December 31, 2014	January 1- December 31, 2014
Unay Un San. ve Tic. A.Ş.		210.731
Sales Returns from Related Parties		210.731
	January 1- December 31, 2014	January 1- December 31, 2014
Unay Un San. ve Tic. A.Ş.		6.973
Sales Discounts to Related Parties		6.973
	January 1- December 31, 2014	January 1- December 31, 2014
Unay Un San. ve Tic. A.Ş.		946.340
General Production Expenses to Related Parties		946.340
	January 1- December 31, 2014	January 1- December 31, 2014
Unay Un San. ve Tic. A.Ş.		21.411.667
Purchase of Raw Material and Supplies from Related Parties		21.411.667

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

	January 1- December 31, 2014
Ulusoy Çay Gıda San. ve Tic. A.Ş.	17.741
Unay Un San. ve Tic. A.Ş.	42.940.639
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	623.965
GK Tarım Ürünleri Depoculuk A.Ş.	48.263
Purchase of Trade Goods from Related Parties	43.630.608
	January 1- December 31, 2014
Unay Un San. ve Tic. A.Ş.	44.242
Ulusoy Petrol Ürünleri Tic. A.Ş.	236.892
Marketing Expenses to Related Parties	281.134
	January 1- December 31, 2014
Ulusoy Çay Gıda San. ve Tic. A.Ş.	1.381
Ulusoy Petrol Ürünleri Tic. A.Ş.	103.117
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	744
General Administrative Expenses to Related Parties	105.242
	January 1- December 31, 2014
Ulusoy Çay Gıda San. ve Tic. A.Ş.	1.310
Unay Un San. ve Tic. A.Ş.	165.902
Other Income from Related Parties	167.212
	January 1- December 31, 2014
Ulusoy Çay Gıda San. ve Tic. A.Ş.	833.669
Unay Gıda Nakliye Sanayi Ticaret Ltd. Şti.	-
Unay Un San. ve Tic. A.Ş.	525.455
Ulusoy Petrol Ürünleri Tic. Limited Şirketi	-
Ulusoy Petrol Ürünleri Tic. A.Ş.	439.882
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	241.920
GK Tarım Ürünleri Depoculuk A.Ş.	-
Interest Income from Related Parties	2.040.926

Top management of The Company consists of board members, general manager and department managers.

Total wage payments and other utilities to top management as of December 31, 2014 is 389.372,69-TL (December 31, 2013: 401.757,62-TL).

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

39. NATURE AND EXTENT OF RISK ARISING FROM FINANCIAL INSTRUMENTS

Liquidity Risk Management:

The principal responsibility related with the liquidity risk management belongs to the Board of Directors. The Board of Directors has created an appropriate liquidity risk management for the short, medium, and long term funding and liquidity requirements of The Company. The Company manages the liquidity risk by monitoring the estimated and actual cash flows on a regular basis and ensuring the continuity of adequate funds and borrowing reserve through matching the maturities of financial assets and liabilities.

Market Risk:

Market risk arises from the probable changes in the level of interest rates, currency exchange rates or the price of securities and other financial contracts that might have an adverse financial impact.

Credit Risk:

The Company's credit risk primarily arises from its trade receivables. Trade receivables are evaluated by The Company's management based on prior experiences and the current economic environment, and presented in the balance sheet on net basis after deducting allowances for doubtful receivables.

40. FINANCIAL INSTRUMENTS (FAIR VALUE EXPLANATIONS AND EXPLANATIONS OF HEDGE ACCOUNTING)

Statement of Foreign Currency Position

Statement of Foreign Currency Position			
December 31, 2014			
	TL (Its functional currency)	USD	Euro
1. Trade and Other Receivables	62.974.658	27.144.251	10.584
2a. Monetary Financial Asset (Include Cash and Bank Account)	39.167.011	16.839.493	41.802
2b. Non-Monetary Financial Assets	-	-	-
3. Futures Market Collaterals	1.357.891	585.576	-
4. Advances Given	1.034.347	446.051	-
5. .Current Assets (1+2+3+4)	104.533.907	45.015.371	52.386
6. Other Non-Current Assets	-	-	-
7. Non-Current Assets	-	-	-
8. Total Assets	104.533.907	45.015.371	52.386
9. Short and Long Term Liabilities			
Loans	17.202.377	3.000.000	3.632.317
Leasing Receivables	266.931	115.111	-
Trade and Other Payables	258.038.749	111.178.292	80.621
Advances Collected	7.159.737	3.084.571	2.455
10. Total Liabilities	282.667.794	117.377.974	3.715.393

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Statement of Foreign Currency Position			
December 31, 2013			
	TL (Its functional currency)	USD	Euro
1. Trade and Other Receivables	61.958.682	29.029.978	93.764
2a. Monetary Financial Asset (Include Cash and Bank Account)	36.379.518	17.020.505	17.931
2b. Non-Monetary Financial Assets	-	-	-
3. Inventories	-	-	-
4. Advances Given	6.351.904	2.976.106	-
5. Current Assets (1+2+3+4)	104.690.104	49.026.589	111.695
6. Other Non-Current Assets	-	-	-
7. Non-Current Assets	-	-	-
8. Total Assets	104.690.104	49.026.589	111.695
9. Short and Long Term Liabilities			
Loans	5.149.009	-	1.753.451
Leasing Receivables	808.929	354.536	17.791
Trade and Other Payables	219.232.423	102.718.654	-
Advances Collected	272.427	127.642	-
10. Total Liabilities	225.462.788	103.200.832	1.771.242

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Foreign Currency Sensitivity Analysis				
December 31, 2014				
	Profit/Loss		Shareholder's Equity	
	Appreciation of foreign currency	Depreciation of foreign currency	Appreciation of foreign currency	Depreciation of foreign currency
Change in 5% of USD Against TL				
1- Net USD Asset/Liability	(8.390.082)	8.390.082	(8.390.082)	8.390.082
2- USD Hedging (-)	-	-	-	-
3- Net USD Effect (1+2)	(8.390.082)	8.390.082	(8.390.082)	8.390.082
Change in 5% of Euro Against TL				
4- Net Euro Asset/Liability	(516.612)	516.612	(516.612)	516.612
5- Euro Hedging (-)	-	-	-	-
6- Net Euro Effect (4+5)	(516.612)	516.612	(516.612)	516.612

Foreign Currency Sensitivity Analysis				
December 31, 2013				
	Profit/Loss		Shareholder's Equity	
	Appreciation of foreign currency	Depreciation of foreign currency	Appreciation of foreign currency	Depreciation of foreign currency
Change in 5% of USD Against TL				
1- Net USD Asset/Liability	(5.781.204)	5.781.204	(5.781.204)	5.781.204
2- USD Hedging (-)	-	-	-	-
3- Net USD Effect (1+2)	(5.781.204)	5.781.204	(5.781.204)	5.781.204
Change in 5% of Euro Against TL				
4- Net Euro Asset/Liability	(243.663)	243.663	(243.663)	243.663
5- Euro Hedging (-)	-	-	-	-
6- Net Euro Effect (4+5)	(243.663)	243.663	(243.663)	243.663

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Credit Risk

December 31, 2014	Receivables				Deposits	Derivative Instruments	Other
	Trade Receivables		Trade Receivables				
	Related Party	Other Party	Related Party	Other Party			
Maximum credit risk as of balance sheet dates (A+B+C+D+E)	1.831.879	175.223.543	-	912.828	62.988.924	3.770.212	7.906.789
- The part of maximum is under guarantee with collateral	-	-	-	-	-	-	-
A. Carrying value of financial assets that not past due nor impaired	1.831.879	175.223.543	-	912.828	62.988.924	3.770.212	7.906.789
B. Net book value of financial assets that terms are reassessed, if not accepted as past due or impaired	-	-	-	-	-	-	-
C. Carrying value of financial assets that past due not impaired	-	-	-	-	-	-	-
- The part under guarantee with collateral etc.	-	-	-	-	-	-	-
D. Net book value of impaired assets	-	-	-	-	-	-	-
- Past due (gross book value)	-	4.317.305	-	-	-	-	-
- Impairment (-)	-	(4.317.305)	-	-	-	-	-
- The part of net value under guarantee with collateral etc.	-	-	-	-	-	-	-
- Not past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- The part of net value under guarantee with collateral etc.	-	-	-	-	-	-	-
E. Off balance sheet items that include credit risk	-	-	-	-	-	-	-

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN
DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

December 31, 2013	Receivables						
	Trade Receivables		Trade Receivables		Deposits	Derivative Instruments	Other
	Related Party	Other Party	Related Party	Other Party			
Maximum credit risk as of balance sheet dates (A+B+C+D+E)	-	103.894.335	512.044	3.059.346	62.758.360	3.314.950	5.411.863
- The part of maximum is under guarantee with collateral	-	-	-	-	-	-	-
A. Carrying value of financial assets that not past due nor impaired	-	103.894.335	512.044	3.059.346	62.758.360	3.314.950	5.411.863
B. Net book value of financial assets that terms are reassessed, if not accepted as past due or impaired	-	-	-	-	-	-	-
C. Carrying value of financial assets that past due not impaired	-	-	-	-	-	-	-
- The part under guarantee with collateral etc.	-	-	-	-	-	-	-
D. Net book value of impaired assets	-	-	-	-	-	-	-
- Past due (gross book value)	-	3.263.026	-	-	-	-	-
- Impairment (-)	-	(3.263.026)	-	-	-	-	-
- The part of net value under guarantee with collateral etc.	-	-	-	-	-	-	-
- Not past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- The part of net value under guarantee with collateral etc.	-	-	-	-	-	-	-
E. Off balance sheet items that include credit risk	-	-	-	-	-	-	-

ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ

NOTES TO THE AUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED THEN DECEMBER 31, 2014

(Amounts expressed in TL, unless otherwise is stated.)

Liquidity Risk

December 31, 2014

Maturities Based on Agreement

Non Derivative Financial Liabilities	Book Value	Cash Outflow According to Contract	Less Than 3 Month	3-12 Month	1-5 Year	More Than 5 Years
Financial Liabilities	46.970.573	46.970.573	1.920.934	41.876.351	3.173.288	-
Debt Securities Issuance	-	-	-	-	-	-
Trade Receivables	263.547.230	263.547.230	-	263.547.230	-	-
Other Payables	30.366	30.366	-	30.366	-	-

December 31, 2013

Maturities Based on Agreement

Non Derivative Financial Liabilities	Book Value	Cash Outflow According to Contract	Less Than 3 Month	3-12 Month	1-5 Year	More Than 5 Years
Financial Liabilities	20.864.884	20.864.884	569.474	18.581.477	1.713.933	-
Debt Securities Issuance	-	-	-	-	-	-
Trade Receivables	221.397.906	221.397.906	-	221.397.906	-	-
Other Payables	2.738	2.738	-	618	2.120	-

December 31, 2014	Receivables		Deposits	Derivative Instruments	Other
	Trade Receivables	Other Receivables			
1-30 days overdue	-	-	-	-	-
1-3 months overdue	-	-	-	-	-
3-12 months overdue	4.317.305	-	-	-	-
1-5 years overdue	-	-	-	-	-
More than 5 years overdue	-	-	-	-	-

December 31, 2013	Receivables		Deposits	Derivative Instruments	Other
	Trade Receivables	Other Receivables			
1-30 days overdue	-	-	-	-	-
1-3 months overdue	-	-	-	-	-
3-12 months overdue	3.263.026	-	-	-	-
1-5 years overdue	-	-	-	-	-
More than 5 years overdue	-	-	-	-	-

41. SUBSEQUENT EVENTS

None.

42. OTHER MATTERS THAT MAY AFFECT THE FINANCIAL STATEMENTS TO A SIGNIFICANT EXTENT OR MATTERS WHICH ARE REQUIRED TO BE EXPLAINED IN ORDER FOR THE FINANCIAL STATEMENTS TO BE CLEAR, INTERPRETABLE AND UNDERSTANDABLE

The Company's financial statements as of December 31, 2013 were audited by another auditor.